Immunomodulatory function of astrocytes characterization and regulation of postanoid metabolism and cytokine synthesis by Johann, Sonja
  
Immunomodulatory function of astrocytes: 
characterization and regulation of  
prostanoid metabolism and cytokine synthesis 
 
 
 
 
 
Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der RWTH 
Aachen University zur Erlangung des akademischen Grades eines Doktors der 
Naturwissenschaften genehmigte Dissertation 
 
vorgelegt von 
 
Diplom-Biologin 
Sonja Johann 
aus Simmern (Hunsrück) 
 
 
 
 
Berichter:  Universitätsprofessor Dr. Herrman Wagner 
Universitätsprofessor Dr. Cordian Beyer 
 
Tag der mündlichen Prüfung: 28.05.2009 
 
 
 
 
 
 
Diese Dissertation ist auf den Internetseiten der Hochschulbibliothek online verfügbar. 
CONTENTS 
ABBREVIATIONS ....................................................................................................................... 1 
1. GENERAL INTRODUCTION ................................................................................................ 2 
1.1 INFLAMMATION..................................................................................................................... 2 
1.2 NEUROINFLAMMATION ......................................................................................................... 2 
1.3 ASTROCYTES DURING CNS PATHOLOGY ............................................................................. 6 
1.4 INFLAMMATORY MEDIATORS IN THE CNS........................................................................... 8 
1.5 LIPOPOLYSACCHARIDE (LPS)-INDUCED INFLAMMATION................................................. 11 
1.6 NUCLEAR HORMONES ......................................................................................................... 12 
1.7 NUCLEAR HORMONES AS MODULATOR OF NEUROINFLAMMATION................................... 15 
2. SCOPE OF THE STUDY....................................................................................................... 18 
3. MATERIAL AND METHODS.............................................................................................. 19 
3.1 PRIMARY ASTROCYTE CULTURE ........................................................................................ 19 
3.2 TREATMENT OF CELL CULTURE ......................................................................................... 19 
3.3 AFFYMETRIX GENE CHIP ARRAY ...................................................................................... 20 
3.4 QUANTITATIVE RT-PCR.................................................................................................... 20 
3.5 SDS- PAGE AND WESTERN BLOT...................................................................................... 21 
3.6 TNF-α, IL-6 AND PGE2 IMMUNOASSAY ............................................................................ 22 
3.7 ANTIBODY ARRAY............................................................................................................... 22 
3.8 LDH ASSAY ......................................................................................................................... 23 
3.9 LIFE DEATH ASSAY .............................................................................................................. 23 
4.  EXPRESSION OF ENZYMES INVOLVED IN THE PROSTANOID METABOLISM 
BY CORTICAL ASTROCYTES AFTER LPS-INDUCED INFLAMMATION.................. 24 
4.1 ABSTRACT ........................................................................................................................... 24 
4.2 INTRODUCTION ................................................................................................................... 25 
4.3 MATERIAL AND METHODS ................................................................................................. 27 
4.4 RESULTS .............................................................................................................................. 29 
4.5 DISCUSSION ......................................................................................................................... 33 
5.   ANTI-INFLAMMATORY EFFECT OF RETINOIC ACID ON PROSTAGLANDIN 
SYNTHESIS IN CULTURED CORTICAL ASTROCYTES................................................. 37 
5.1 ABSTRACT ........................................................................................................................... 37 
5.2 INTRODUCTION ................................................................................................................... 38 
5.3 MATERIAL AND METHODS ................................................................................................. 40 
5.4 RESULTS .............................................................................................................................. 42 
5.5 DISCUSSION ......................................................................................................................... 52 
5.6 ACKNOWLEDGEMENTS ....................................................................................................... 57 
6.  BRAIN REGION-SPECIFIC ASTROGLIAL RESPONSES IN VITRO AFTER LPS 
EXPOSURE ................................................................................................................................. 58 
6.1 ABSTRACT ........................................................................................................................... 58 
6.2 INTRODUCTION ................................................................................................................... 59 
6.3 MATERIAL AND METHODS ................................................................................................. 60 
6.4 RESULTS .............................................................................................................................. 62 
6.5 DISCUSSION ......................................................................................................................... 68 
7. ESTROGEN AND PROGESTERONE REDUCE LPS-INDUCED EXPRESSION OF 
TNF-ALPHA AND INTERLEUKIN-18 IN MIDBRAIN ASTROCYTES ........................... 72 
7.1 ABSTRACT ........................................................................................................................... 72 
7.2 INTRODUCTION ................................................................................................................... 73 
7.3 MATERIAL AND METHODS ................................................................................................. 74 
7.4 RESULTS .............................................................................................................................. 74 
7.5 DISCUSSION ......................................................................................................................... 77 
7.6 ACKNOWLEDGMENTS ......................................................................................................... 78 
8. GENERAL DISCUSSION...................................................................................................... 79 
9. SUMMARY.............................................................................................................................. 83 
10. ZUSAMMENFASSUNG ...................................................................................................... 85 
11. ACKNOWLEDGEMENT.................................................................................................... 87 
12. REFERENCES...................................................................................................................... 88 
 
 
 
 
 
 
 
LIST OF FIGURES 
Figure 1. The neurovascular unit.................................................................................................................. 5 
Figure 2. Cell-surface recognition of LPS.................................................................................................. 12 
Figure 3. Retinoic acid synthesis and signaling ......................................................................................... 14 
Figure 4. Cellular signaling and transduction mechanisms of steroid hormones ....................................... 15 
Figure 5. The effect of LPS-treatment on the expression pattern of enzymes involved in prostanoid 
metabolism .................................................................................................................................................. 31 
Figure 6. Time-course of LPS-induced (12 h, 100 ng/ml) stimulation of COX-2 (A) and COX-1 (B) 
mRNA expression, and production of PGE2 (C) in cortical astrocytes ....................................................... 32 
Figure 7. The effect of dexamethasone (DEX) and the COX-2 inhibitor NS-398 on LPS-mediated 
regulation of enzymes involved in prostanoid metabolism as well as on PGE2 production in cortical 
astrocytes. .................................................................................................................................................... 33 
Figure 8. Treatment of astrocytes with lipopolysaccharides (LPS) and retinoic acid (RA) does not affect 
cell viability................................................................................................................................................. 45 
Figure 9. Prostaglandin (PG) synthesis in cortical astrocyte cultures ........................................................ 45 
Figure 10. Retinoic acid (RA) influences the effects of lipopolysaccharide (LPS) on expression of 
enzymes necessary for prostaglandin metabolism. ..................................................................................... 47 
Figure 11. Enzyme expression of leukotriene metabolism is reduced by lipopolysaccharide (LPS) but not 
affected by additional retinoic acid (RA) treatment. ................................................................................... 48 
Figure 12. Retinoic acid (RA) reduces the lipopolysaccharide (LPS) - dependent protein expression of 
cyclooxygenase-2 (COX-2)......................................................................................................................... 49 
Figure 13. Retinoic acid reduces the LPS-induced synthesis of prostaglandin E2. Astrocyte cultures were 
treated as described for gene expression analysis. ...................................................................................... 50 
Figure 14. Retinoic acid influences basal expression of prostaglandin metabolizing enzymes ................. 51 
Figure 15. Expression of different cytokines in cultured (A) cortical (Cx) and (B) midbrain (Mes) 
astrocytes detected by a cytokine protein chip assay. ................................................................................. 64 
Figure 16. Regional differences in basal cytokine and chemokine expression of astrocytes. .................... 65 
Figure 17. Regional differences in LPS-induced cytokine and chemokine expression of astrocytes. ....... 66 
Figure 18.Time-course of LPS-induced (12 h, 100 ng/ml) stimulation of TNF-α mRNA (A) and TNF-
α protein (B) expression.............................................................................................................................. 67 
Figure 19. Time-course of LPS-induced (12 h, 100 ng/ml) stimulation of IL-6 mRNA (A) and IL-6 
protein (B) expression. ................................................................................................................................ 68 
Figure 20. Effect of estrogen (E, 10-8M) and progesterone (P, 10-8M) pre-treatment (24 h) on LPS-
induced (4 h) tumour necrosis factor-alpha (TNF-α expression in midbrain and cortical neonatal 
astrocytes. .................................................................................................................................................... 75 
Figure 21. Effect of estrogen (E, 10-8M) and progesterone (P, 10-8M) pre-treatment (24 h) on LPS-
induced (4 h) interleukin-18 (IL-18) expression in midbrain and cortical astrocytes. ................................ 76 
 
  
LIST OF TABLES 
Table 1. Primer sequences used for quantitative real-time RT-PCR .......................................................... 28 
Table 2. Regulation of enzymes involved in prostanoid metabolism in cortical astrocytes analyzed by 
Affymetrix Gene Chip array........................................................................................................................ 30 
Table 3. Primer sequences used for quantitative RT-PCR ......................................................................... 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
Aß  Amyloid ß peptide 
AA  Arachidonic acid 
AD  Alzheimer’s disease 
ALOX-5 5-lipoxygenase 
ALS  Amyotrophic lateral sclerosis 
APP  Amyloid precursor protein 
APS  Ammonium persulfat 
BBB  Blood brain barrier 
BSA  Bovine serum albumin 
cDNA  Complementary 
deoxyribonucleic acid 
CNS  Central nervous system 
COX  Cyclooxygenase 
CRABP Cellular retinoic acid binding 
protein 
CRE cAMP response element 
CREBP Cellular retinol binding protein 
DEPC  Diethyl-pyrocarbonate 
DEX  Dexamethasone 
DMEM Dulbecco’s Modified Eagle’s 
Medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  2’-deoxyribonucleoside-5’-tri-
phosphate 
E Estrogen 
E. coli  Escherichia coli 
ECL  Enhanced chemilumeniscence 
EDTA  Ethylendiamine-tetra acetic acid 
EIA  Enzyme immunoassay 
ER  Estrogen receptor 
FCS  Fetal calf serum 
 
FDA Food and Drug 
Administration  
GFAP  Glial fibrillary acidic protein 
HPGD  15-hydroxy prostaglandin 
dehydrogenase 
 
HPRT  Hypoxanthin-guanin-
phosphoribosyl-transferase 
HRE Hormone response element 
IL  Interleukin 
iNOS  inducible nitric oxide synthase 
 
 
 
kDa  Kilo dalton 
LDH  Lactat dehydrogenase 
LPS  Lipopolysaccharides 
M  Molar 
NF-κB  Nuclear factor-κB 
NO  Nitric oxide 
NSAID  Non-steroidal anti-inflammatory 
drug 
OD  Optical density 
PAGE  Polyacrylamide gel 
electrophoresis 
P Progesterone 
PBS  Phosphate bufferd saline 
PCR  Polymerase chain reaction 
PFA  Paraformaldehyde 
PG  Prostaglandin 
PGDS  Prostaglandin D synthase 
PGE2  Prostaglandin E2 
PGER  Prostaglandin E2 receptor 
PLA2  Phospholipase A2 
PMSF  Phenylmethylsulfonylfluorid 
PTGES Prostaglandin E2 synthase 
PTGIS  Prostacyclin synthase 
PTGIR Prostacyclin receptor 
PR  Progesterone receptor 
RA  Retinoic acid 
RALDH Retinaldehyde dehydrogenase 
RAR  Retinioc acid receptor 
RARE  Retinoic acid response element 
RNA  Ribonucleic acid 
RPM  Rounds per minute 
RT  Reverse transcription 
RXR  Retinoic X receptor 
SEM  Standard error of the mean 
SD  Standard deviation 
SDS  Sodium-dodecylsulfate 
TBS  Tris-buffered saline 
TBXAS Thromboxane-A synthase 
TBXs  Thromboxanes 
TEMED N,N,N’,N’-
tetramethylethylendiamine 
TLR-4  Toll-like receptor 4 
Tris  Tris-(hydroxymethyl) 
aminomethane 
WB  Western Blot
 1
 2 
1. GENERAL INTRODUCTION 
1.1 Inflammation 
Inflammation is a host defense to tissue damage, infections, and oxidative stress. Inflammatory 
processes are triggered in response to infection, damage, and ischemia, and are characterized by 
several cardinal features such as swelling, redness, heat, and pain. Moreover, the definition of 
inflammation is also manifested by the invasion of immune cells (macrophages, lymphocytes, 
and neutrophils) to the injured site and by the local production of pro-inflammatory mediators, 
ultimately leading to the abatement of the invading agent and damaged tissue. Inflammatory 
responses have their benefits for tissues and cells, at first glance, due to the timely balanced local 
activation and regulation of the immune system which is necessary to eliminate destructed cells 
and cell material. An inappropriate, overshooting, or persistent inflammation may significantly 
influence the pathogenesis of chronical and degenerative disorders including rheumatoid arthritis, 
inflammatory bowl disease, and different autoimmune diseases (McGeer and McGeer, 2004). 
 
1.2 Neuroinflammation 
The central nervous system (CNS) is an immune-privileged organ, since it lacks resident 
dendritic cells, and the expression of major histocompatibility complex antigens (MHC) on brain 
cells is very low. The inflamed brain does not show the characteristic signs of pain, redness, or 
swelling which are typically observed during peripheral inflammation. This epiphenomenon is 
the result from a lack of sensory nerve endings, lymphatic vessels, and other mechanisms 
regulating tissue fluid composition. The previous concept that the brain is unaffected by systemic 
inflammation had to be revised over a decade ago. This reflects the ability of the CNS to fight 
infections notwithstanding its immune-privileged position. The blood-brain-barrier (BBB) is an 
important structure specialized for maintaining brain homeostasis and restricting invasion of 
pathogens and immune cells to the brain parenchyma. While leukocyte invasion may be delayed 
in response to acute brain injury, local activation of glial cells occurs within minutes or hours. 
Today, there is no doubt that CNS inflammation, called neuroinflammation, contributes to many 
neurological disorders, including acute injuries such as stroke and other ischemic processes as 
well as chronic diseases like multiple sclerosis (MS) or Alzheimer’s and Parkinson’s disease 
(Akiyama et al. 2003; Danton et al. 2003; McGeer and McGeer 2004).  
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1.2.1 Immune competent cells of the CNS 
There is compelling evidence that all types of neural cells, e.g. glial cells such as astrocytes, 
oligodendrocytes, and microglia, as well as neurons contribute to some extent to brain 
inflammatory responses (Lucas et al., 2006). More than 70% of the total brain cell population 
consists of glial cells, including the three cell types mentioned above. Glia cells get in close 
physical contact with neurons during brain inflammation, show increased local proliferation 
rates, and, in addition, secrete a variety of diffusible factors often in a temporarily coordinated 
fashion. Thus, a complex cell-cell interrelationship exists between the different subforms of glial 
cells and neurons involving direct interactions and paracrine regulation by diffusible factors. 
The major cellular mediators of neuroinflammatory processes within the CNS are microglia cells. 
Microglia regarded as brain resident macrophages are of mesodermal origin. They invade the 
CNS during development. This cell type shares many characteristics with peripheral 
macrophages concerning their immunological and functional properties (Davis et al. 1996). 
Microglia is susceptible to any disturbances of the brain environment. Once activated, microglial 
cells migrate to the injured site and actively remove dead cells and cellular debris. Most studies 
in the field of neuroinflammation in the past years had their focus on the contribution and 
regulation of microglia during inflammation. In contrast, the precise role of the other glial cell 
types has often been neglected. Recent studies, however, revealed that, in particular, astrocytes 
exhibit a complex, dual role in the regulation of neural immune response (Dong and Benveniste, 
2001; Farina et al., 2007).  
Since the main focus of this thesis is concerned with the importance and participation of 
astrocytes during neuroinflammation, the properties of this cell type will be discussed in more 
detail.  
 
1.2.2 Astrocytes 
Astrocytes are of neuroectodermal origin and constitute the main glial cell population in the 
brain. Their name refers to the starlike shape of process arrangement observed in histological 
preparations but their morphology can vary extremely ranging from “bipolar-like” thin cells with 
long processes to “fried egg-like” multipolar cells. These morphological features may be seen in 
the context of reactive responses of this cell type to the physiological demands and may reflect 
functional adaptations of an astrocyte to developmental/adult processes, regular/irregular events 
and brain region-specific position. Although they account for almost half the brain cells, their 
function has been a long-standing mystery. Astrocytes were for decades considered as passive 
cells only providing metabolic and structural support to neurons. This view has been 
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reconsidered during recent years. Nowadays, it is clear that astrocytes are involved in the 
regulation of metabolic support of neurons, energy metabolism, free-radical scavenging, synaptic 
transmission, and neuronal excitability including neurotransmitter and ion homeostasis (Bezzi 
1999, Walz 2000). It is less-recognized that astrocytes are not just single cells but form large 
functional networks due to the expression of gap junctions which allows the propagation of 
calcium waves as well as the share of other low molecular weight compounds such as ATP and 
potassium (Koehler et al., 2006). This is a very important point for understanding how astrocytes 
contribute to the spreading of damage from an initiating central point. The astrocytic syncytia 
also appears significant for intercellular communication, maintaining the homeostasis of the 
extracellular fluid, and trafficking of glucose and other substances from the blood-brain interface 
(Walz, 2000; Wallraff et al., 2006). Astrocytes are crucial for the morphological and 
physiological formation of a functional BBB in the CNS. The BBB is made up by non-
fenestrated endothelial cells that develop tight junctions among adjacent cells and is classically 
considered to be a physical and metabolic barrier restricting and controlling the entry of blood-
borne substances into the brain. In vitro studies have demonstrated that endothelial cells alone 
cannot provide a tight barrier without the presence of astrocytes (Deli and Joo, 1996; Risau et al., 
1998). Astrocyte processes form highly specialized domains, so called endfeets that are located at 
the perivascular membrane (Figure 1). The presence of specific proteins, including the water 
channel aquaporin 4 (AQP4) and Kir4.1 K+ channel (Neely et al., 2001; Amiry-Moghaddam and 
Ottersen, 2003; Nagelhus et al., 2004) in the endfoot membrane is characteristic for these 
structures. 
Under normal physiological conditions, astrocytes are more important than microglia for 
retaining and supporting nerve cell functions. Astrocytes handle the uptake and the recycling of 
the primary excitatory neurotransmitter glutamate from the extracellular space by glutamate 
transporters (GLT-1 and GLAST) and returning glutamine back to neurons through the 
glutamate-glutamine shuttle (McKenna, 2007). They secrete a large number of neurotrophic 
factors, including ciliary neurotrophic factor (CNTF) and insulin-like growth factor (IGF) 
(Chernausek 1993; Moretto et al. 1994; Rudge et al. 1994). These molecules are essential for 
proliferation, survival, and maturation of developing neurons (Villegas et al., 2003). 
Following brain injury, astrocytes shift to an activated status and migrate towards the affected 
area where they form a glial scar around the damaged tissue. Bush et al. (1999) showed that the 
loss of glial scar formation after injury was associated with degeneration of neurons, dysfunction 
of the BBB and prolonged invasion of CD45+ leukocytes. One important function of activated 
astrocytes is their participation in immune functions in the CNS. They seem to play an important 
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role in microglial activation and deactivation at different levels. During CNS injury, microglia 
and astrocytes release the pro-inflammatory cytokine TNF-α which can cause further brain 
damage by promoting gliosis, inhibiting glutamate uptake, and inducing apoptosis (Selmaj et al., 
1991; Fine et al., 1996). 
The population of astrocytes appears to be heterogeneous in function. Several studies have 
provided evidence that half of the astrocyte population shows “typical” properties like high 
GFAP expression, extensive gap junctions coupling, and a low input resistance. On the other 
hand, the remaining population provides a large input resistance, low gap junction coupling and 
GFAP expression (Matthias et al., 2003; Grass et al., 2004; Wallraff et al., 2004). Many 
neurological diseases exhibit characteristic features of brain-region specific pathological 
reactions and cell loss. Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are 
neurodegenerative disorders characterized by the selective loss of neurons in specific brain areas, 
e.g. dopaminergic neurons in the substantia nigra and motor neurons in the cortex, brainstem, and 
spinal cord (Forno, 1996; Barbeito et al., 2004). This phenomenon might be associated with a 
functional divergence of astrocytes in different brain regions. Recent findings propose that 
astrocytes have brain region-specific properties and diverge in their reaction to pathological 
stimuli (Kipp et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The neurovascular unit. A conceptual framework, the neurovascular unit comprises neurons, the 
microvessels that supply them, and their supporting cells. Cerebral microvessels consist of the 
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endothelium (which forms the BBB), the basal lamina matrix, and end-feet of astrocytes. Microglial cells 
and pericytes may also participate in the unit. Communication has been shown to occur between neurons 
and microvessels through astrocytes (adapted from del Zoppo, 2006). 
 
1.3 Astrocytes during CNS pathology 
Functional impairments as well as physiological reactions of astrocytes to brain injury have the 
potential to induce neuronal dysfunction. Astrocytes play an important role in the secondary 
amplification of cell injuries during several neurological disorders (Maragakis and Rothstein 
2006). The physiological process of aging is also accompanied by various glial pathologies, 
including astrogliosis and swelling of astrocytic processes. Astrocytes can produce various pro-
inflammatory molecules which play an important role in the regulation of gene transcription and 
signal function, and in the induction and maintaining of inflammatory responses (Dong and 
Benveniste, 2001).  
 
1.3.1 Cerebral ischemia 
Brain ischemia results from cardiac arrest, stroke, or head trauma. Ischemic events lead to severe 
brain damage which causes long-term disability. Stroke is one of the leading reasons of disability 
and death in humans. Research has long focused on the understanding of necrosis and apoptosis 
of neurons because they are the most susceptible cell type to ischemia. Today, we have learned 
that astrocytes have various, significant roles during ischemia. After a 30 min period of focal 
ischemia, metabolism is equally impaired in neurons and astrocytes (Hagberg et al. 2001). The 
primary consequences during ischemia are the loss of glucose and oxygen which reduces ATP 
synthesis through glycolysis and oxidative phosphorylation. However, there are presumably large 
reserves of alternative substrates for glycolysis and respiration, such as glycogen, lactate, or fatty 
acids. Oxygen is an irreplaceable component of mitochondrial respiration, and the lack of oxygen 
immediately leads to decreased ATP production. Upon loss of intracellular ATP, inhibition of the 
Na+-K+ ATPase results in a profound loss of ionic gradients and membrane depolarization in 
neurons and astrocytes. The interruption of oxidative phosphorylation can, in addition, promote 
an increase in reactive oxygen species (ROS). Under these conditions, the physiological and 
supportive function of astrocytes, including glutamate uptake, free-radical scavenging, and K+-
buffering may be impaired. Reduced uptake and increased release of glutamate by astrocytes 
culminates in a pronounced elevation of intracellular calcium in neurons and astrocytes. This 
cascade of events triggers neuronal and subsequently astrocytic cell death, known as 
excitotoxicity. Since astrocyte gap junctions remain open during ischemia, this may contribute to 
 7 
cell death due to a transcellular spread of pro-apoptotic signals from dying astrocytes in the 
ischemic core to surrounding viable cells (Lin et al. 1998). However, astrocytes differ from 
neurons in numerous important aspects that make them less vulnerable to ischemic damage. 
During ischemia astrocytes are able to maintain constant ATP levels for a longer period than 
neurons, and they posses a lower density of ionotropic buffering and antioxidant capacity (Silver 
et al., 1997; Xie et al., 2007).  
 
1.3.2 Amyotrophic lateral sclerosis (ALS) 
The pathology of ALS is characterized by a selective and progressive degeneration of alpha- 
motoneurons in the spinal cord, cortical and brainstem motoneurons, leading to the characteristic 
symptoms such as paralysis, spasticity, and muscle atrophy (Barbeito et al., 2004). Research on 
ALS has mainly focused on the mechanism of motoneuron death. An important step in 
understanding the pathogenesis of ALS was provided by the development of a transgenic mouse 
model of ALS/SOD1. A change in SOD1 protein structure leads to a gain of function that is 
specifically toxic to motor neurons.  It was shown that astrocytes undergo morphological and 
functional changes, including reduced expression of the glial glutamate transporter GLT-1 and 
vacuolization of mitochondria (Howland et al., 2002). Glial-glial cross-talk appears to be the 
basis of ALS pathogenesis. Activated microglia might release pro-inflammatory mediators that 
cause astrocytic activation and expression of cytokines, chemokines, and growth factors. For 
example, the expression of the pro-inflammatory COX-2 is elevated in the spinal cord of ALS-
patients (Yasojima et al. 2001). Increased expression of cyclooxygenase 2 (COX-2) and a 
coherent production of prostaglandin E2 can stimulate glutamate release of astrocytes (Bezzi et 
al., 1998). Studies of sporadic ALS have suggested that an excitotoxic mechanism promotes the 
development and progression of this disease, as ALS patients demonstrate elevated levels of 
glutamate in the spinal cord and cerebrospinal fluid and decreased glutamate transporter activity 
(Rothstein et al., 1995). The reduced capacity of astrocytic glutamate uptake in ALS (Barbeito et 
al., 2004) and the subsequent increase in extracellular glutamate levels might promote 
excitotoxicity. Riluzole, a glutamate-antagonist, is currently the only FDA-approved (Food and 
Drug Administration) drug for ALS (Lacomblez et al., 1996). 
 
1.3.3 Alzheimer’s disease (AD) 
Alzheimer’s disease is an age-related, progressive neurodegenerative disorder and the most 
common form of dementia in later life. It is manifested by progressive memory impairment, 
language difficulties, deficits in motor spatial skills (apraxia), and visual spatial skills (agnosia). 
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Histopathological features are the presence of neurofibrillary tangles and senile plaques. Senile 
plaques are deposits of extracellular amyloid beta peptide (Aβ) and neurofibrillary tangles 
composing of hyperphosphorylated tau protein are found intracellularily (Braak and Braak 1997; 
Dickson, 1997). Beta-amyloid is a fragment from a larger protein called amyloid precursor 
protein (APP), a transmembrane protein highly expressed in the brain. The amyloid precursor 
protein is critical to neuron growth, survival, and post-injury repair. Expression of APP is up-
regulated during neuronal differentiation and after neural injury. The APP gene family plays an 
essential role in the development of the nervous system relating to synapse structure and 
function, as well as in neuronal migration or adhesion (Zheng and Koo, 2006). 
Alzheimer’s disease is characterized by the loss of cholinergic and cholinoceptive neurons 
(especially in the frontal cortex and hippocampus) and the presence of activated macrophages 
and astrocytes (Nagele et al., 2003). Reactive astrocytes can be found in the surrounding of senile 
plaques. Astrocytes activated by Aβ produce a set of cytokines including IL-1β, TNF-α, 
chemokines, and prostanoids, reactive oxygen species as well as complement proteins which can 
directly cause neuronal damage (Akiyama et al., 2000). Chemokines released by astrocytes may 
attract microglia which, in addition, are stimulated to release further pro-inflammatory molecules 
and, thereby, enhance neuronal injury (Tuppo and Arias, 2005). Higher levels of NOS-positive 
astrocytes are found in AD brains compared to control brains (Simic et al., 2000). Besides other 
pathological mechanisms, neuronal damage during AD may be the result from inflammatory 
reactions involving free radical production and cytokine release rather from the presence of 
amyloid or tau per se. Thus, the inhibition of inflammation may delay or even abort the loss of 
neurons as a consequence of amyloid deposition. 
 
1.4 Inflammatory mediators in the CNS 
Many inflammatory mediators, including cytokines, chemokines, and prostanoids have only 
modest functions in the healthy brain tissue and are expressed at very low or untraceable levels. 
In response to brain injury or infection, their synthesis capacity rapidly increases and they are 
releases in the extracellular space. 
 
1.4.1 Cytokines and chemokines 
Cytokines are key regulators of the innate and adaptive immune response. They act through 
specific receptors which are coupled to distinct signal transduction or second messenger 
pathways to broadcast signals from the extracellular milieu to the cell nucleus. In the CNS, 
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numerous cytokines are known to be up-regulated after injury, infection, and during neurological 
diseases (Lucas et al., 2006). This includes the pro-inflammatory mediators IL-1β, IL-6 and 
TNF-α. TNF-α and IL-1β can cause a BBB breakdown by inducing the expression of 
chemokines and adhesion molecules which facilitate the invasion of leukocytes into the CNS 
(Lee and Benviste, 1999; Sedgwick et al., 2000). Both cytokines are acknowledged to induce the 
expression of iNOS and trigger the release of NO from glial cells (Bonmann et al., 1997). 
Increased production of NO can cause neuronal cell death during ischemia and 
neurodegenerative diseases (e.g. AD, PD, ALS) (Liu et al., 2002). 
Chemokines play a decisive role in the recruitment of leukocytes from the blood into the CNS 
and the migration of cells, including microglia (Ubogu et al., 2006). Chemokines are 8-10 kDa 
proteins with four conserved cysteines and have been divided into four subfamilies based on the 
relative position of their cysteine residue (CXC, CC, C, and CX3C). They interact with receptors 
that have seven G protein-coupled transmembrane domains expressed on a wide variety of 
immune and non-immune cells (Zlotnik and Yoshie, 2000). The main sources of chemokines 
during CNS inflammation are endothelial cells, astrocytes, and microglia (Hesselgesser and 
Horuk 1999). Chemokines of the CXC family (IL-8, IP-10) and of the CC family (MIP-1α, MIP-
1β, MCP-1 and RANTES) are produced by microglia and may contribute to the recruitment of T-
cells, macrophages, and dendritic cells to the CNS parenchyma (De Groot and Woodroofe 2001). 
Astrocytes were shown to release IP-10, IL-8, MCP-1 and RANTES but not MIP-1 and MIP-2 
upon stimulation with LPS, viruses, and pro-inflammatory cytokines (IL-1β and TNF-α) (Hua 
and Lee, 2000; Kipp et al., 2008). Growing evidence suggests that chemokines can stimulate the 
migration of microglia to damaged or inflammatory brain sites (Rappert et al., 2004; Marella and 
Chabry, 2004). Cytokines and chemokines have multiple actions in the CNS which are important 
during inflammation and the progression of neurodegeneration. The expression of several 
chemokine and cytokine receptors has been described in the brain (Bajetto et al. 2001; Szelenyi, 
2001).  
 
1.4.2 Prostanoids 
Another type of pro-inflammatory mediator produced by activated microglia and astrocytes are 
prostanoids. Prostanoids are a large group of arachidonic acid (AA) metabolites composed of: 
prostaglandins, thromboxanes, and prostacyclins. Interest in the role of prostaglandins emerged 
in the 1960s revealing that they might exhibit a neuro-humoral function. Prostaglandins (PGs) 
are widely distributed in the CNS (Horton and Main, 1967). In the rat cortex, PGs appear to be 
stored in vesicles (Kataoka et al., 1967). Prostaglandins are local paracrine and autocrine 
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mediators of inflammation (Minghetti, 2004). Under regular physiological conditions, PG levels 
in the cortex are very low. In contrast, levels dramatically increase under pathological conditions, 
such as ischemia, injury, and inflammation. Prostaglandins are implicated in numerous 
physiological and pathophysiological processes in the brain (Bazan et al., 1994; Minghetti, 
2004). The release of AA from membrane phospholipids is mediated by multiple forms of 
phospholipase A2 (PLA2). Three PLA2 subtypes are known to be expressed in the CNS: a 
secretory PLA2 (sPLA2), a cytosolic PLA2 (cPLA2), and a calcium-independent PLA2 (iPLA2) 
(Murakami and Kudo, 2002). Both, sPLA2 and cPLA2, appear to be involved in inflammatory-
mediated PG production by astrocytes (Xu et al., 2003). In the CNS, elevated levels of cPLA2 
have been found in activated astrocytes and microglia after cerebral ischemia (Clemens et al., 
1996). 
Arachidonic acid is the substrate for the cyclooxygenase (COX), the key enzyme for PG 
synthesis. Cyclooxygenase (COX) is a heme-containing bifunctional enzyme with two catalytic 
centers. The cyclooxygenase centre adds oxygen to AA to form PGG2 and a peroxidase centre 
where PGG2 is reduced to PGH2. PGH2 serves as substrate for the generation of several bioactive 
prostaglandins, including prostaglandin E2 (PGE2), prostaglandin I2 (PGI2), and prostaglandin D2 
(PGD2). The COX enzyme exists in two isoforms, known as COX-1 and COX-2 which are 
encoded by two different genes. COX-1 is referred to be expressed constitutively in many 
tissues, while COX-2 is induced in response to inflammatory stimuli (Tanabe and Tohnai, 2002). 
COX-1 and COX-2 are homodimers and share about 60% at the amino acid level and have 
comparable kinetic properties (Smith et al., 2000). The COX-2 gene contains a number of 
regulatory binding sites, including nuclear factor-κB (NF-κB), IL-6 response element, AP-2, and 
the cyclic AMP-response element (Tanabe and Tohnai, 2002). Prostaglandins produced via the 
COX-2 pathway are, therefore, usually considered to act in a pro-inflammatory manner, whereas 
those formed by COX-1 are thought to have an important role in maintaining brain homeostasis 
(Farooqui et al., 2007). Recently, a COX-1 splice variant (putative COX-3) was detected in 
murine tissues and glial cells (Shaftel et al. 2003). COX-3 which retains intron 1 in the mRNA 
sequence does not seem to be implicated in inflammatory responses (Shaftel et al., 2003). The 
degradation of PGE2 and other prostaglandins is mediated by the 15-hydroxy prostaglandin 
dehydrogenase (HPGD) which converts PGE2 to inactive metabolites (Ivanov and Romanovsky, 
2004). The inhibition of COX-2 is neuroprotective in animal models for ischemia and ALS 
(Iadecola et al., 2001; Klivenyi et al., 2004). Selective inhibitors of COX-2 have also confirmed 
that this enzyme plays a critical role in inflammation, pain, and fever (DeWitt, 1999).  
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1.5 Lipopolysaccharide (LPS)-induced inflammation 
Bacterial motifs which are recognized by the innate immune system have been called pathogen-
associated molecular patterns (PAMPs) (Janeway and Medzhitov, 1998). PAMPs can have 
different chemical structures. They can be fragments of bacterial cell walls (lipopolysaccharide, 
lipoteichoic acid, and peptidoglycan), bacterial and viral DNA fragments, flagellin (a protein 
derived from the bacterial flagella), viral RNA, or fungal proteins (zymosan). LPS is widely used 
to provoke inflammatory cell responses in vitro and in vivo. The main PAMP derived from gram-
negative bacteria will be discussed below. 
 
1.5.1 Pathogen-associated molecular pattern (PAMP) of LPS 
LPS is a constituent of the outer membrane of gram-negative bacteria and wildly used to 
stimulate an inflammatory reaction in vitro. LPS is one of the best studied bacterial products and 
has been shown to be a powerful immunostimulator. The molecular and cellular mechanisms of 
LPS-mediated responses of the innate immune system are well-understood (Palsson-McDermott 
and O’Neill, 2004). Circulating LPS binds to the LPS-binding protein (LBP) and to the opsonic 
receptor CD-14 (Cohen, 2002). CD-14 is a glycosylphosphatidylinositol-linked molecule 
anchored on the cell surface. The fact that membrane-bound CD-14 has no intracellular tail leads 
to the question how the LPS-LBP complex can cause cellular activation. This lack of clarity was 
solved by the discovery of the family of Toll-like receptors (TLRs). The CD-14/LPS complex 
reacts with the Toll-like receptor 4/myeloid differentiation protein (MD-2) complex which is 
necessary for LPS-induced signal transduction (Cohen, 2002). Myeloid differentiation primary 
response gene (88) (Myd88) and MyD88 adapter-like (MAL) are further adaptor proteins for 
TLR-4 signaling. TLRs contain an intracellular domain that is homologous to the IL-1 and IL-18 
receptor. Adapter proteins assist the binding to IL-1 receptor-associated kinase (IRAK) which, in 
turn, induces TNF receptor-associated factor-6 (TRAF6), leading to nuclear translocation of 
nuclear factor-κB (NF-κB), and finally to the activation of cytokine gene promoters (Figure 2) 
(Cohen, 2002).  
The innate immune system also exists in the CNS, and its main responses are mediated by 
microglia and astrocytes. Glial cells recognize pathogens and become activated leading to the 
evolution of inflammation. Microglia and astrocytes have been shown to respond to LPS with the 
release of a wide spectrum of inflammatory cytokines, arachidonic acid derivates, reactive 
oxygen species (ROS), and nitric oxide (NO) (Heine et al., 2001; Lee and Lee, 2002, Kipp et al. 
2008)). Recently, it has been shown that LPS-stimulated microglia and astrocytes generate pro-
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inflammatory factors which contribute to neuronal death (Cai et al., 2003; Bal-Price and Brown, 
2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cell-surface recognition of LPS  
The principal mechanism by which LPS is sensed occurs via a LPS-binding protein (LBP)–LPS complex 
and further signaling through the Toll-like receptor 4 (TLR4)-MD-2 complex. Other cell surface 
molecules also recognize LPS; these include the macrophage scavenger receptor (MSR), CD11b/CD18, 
and ion channels (adapted from Cohen, 2002). 
 
1.6 Nuclear hormones 
The regulation of gene expression has become a central theme in the field of molecular biology. 
Lipophilic hormones are prominent candidates to act as potent modulators of this process. These 
hormones, including steroids (estrogen, progesterone, and testosterone) and non steroidal 
lipophilic hormones (all-trans-retinoic acid, thyroid hormone and vitamin D3) are essential 
regulators of physiological processes such as development, reproduction and cell differentiation 
(Blomhoff and Blomhoff, 2006; Brann et al., 1995; Dusso et al., 2005). The brain is an important 
target for circulating lipophilic hormones such as sex steroids or retinoids. These hormones 
strongly influence brain development, cognition, behaviour, memory, and may also have a strong 
impact on neuroprotective processes (Kajta and Beyer, 2003; Mey, 2004).  
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1.6.1 Retinoids: Retinoic acid (RA) signaling  
Recently, RA signaling in the brain has been implicated under physiological and non-
physiological conditions such as cell proliferation and differentiation, learning and memory 
processes, Huntington’s (Luthi-Carter et al., 2000) and Parkinson’s (Fisher, 1998) and motor 
neuron disease (Corcoran et al. 2002b). Retinoic acid is synthesized from blood-derived vitamin 
A and regulates gene activity by binding to nuclear receptors (Bastien and Rochette-Egly, 2004). 
The majority of vitamin A is converted to retinol in the intestinal lumen and mucosa. Storage of 
retinol mainly occurs in the liver where it is transported to the target cells. Because of its 
lipophilic character, it can diffuse freely through the plasma membrane. Retinol can be 
metabolized to the bioactive derivative, all-trans-retinoic acid (ATRA) which exerts the most 
powerful effects in biological systems and is, therefore, the best studied vitamin A derivative. 
Biosynthesis of ATRA is catalyzed by cytosolic alcohol dehydrogenase (ADH) which converts 
retinal to retinal. Retinal is further oxidized to ATRA by retinal dehydrogenase (RALDH) 
(Figure.3). The action of ATRA is mediated by nuclear retinoid receptor proteins termed retinoic 
acid receptors (RAR-α, β, and γ) and retinoid “X” receptors (RXR-α, β, and γ) (Mey et al., 
2005). These receptors belong to the steroid receptor superfamily and function as transcriptional 
modulators. The RA receptors RAR and RXR can form heterodimers, but activation of RAR-
RXR induced gene transcription by ATRA is mainly controlled via RAR (Kurokawa et al., 
1994). The active transcription factor complex RAR/RXR which also includes ligands and 
coactivators interact with retinoic acid response elements (RAREs) in the promoter region of 
target genes. A multitude of genes, transcription factors, and cytokines contain functional RAREs 
or RXREs and are proven targets for RA, including IL1-α, IL1-β and TNF-α (McCaffery and 
Dräger, 2000; Mey, 2001). RA contributes to the development of interneurons and motor neurons 
in the embryonic spinal cord (Shiga et al., 1995; Sockanathan et al., 2003). In retinoid-deficient 
rats, motor neurons showed an accumulation of intracellular neurofilaments, increased 
astrocytosis, and motor neuron degeneration. These events have been attributed to a deficiency of 
RAR-α  activation (Corcoran et al., 2002b). 
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Figure 3. Retinoic acid synthesis and signaling 
Retinoic acid acts via ligand-activated transcription factors that regulate a number of genes involved in 
neuronal and glial differentiation. In addition to the direct transcriptional control, many target genes are 
regulated in a non-genomic way (adapted from Mey, 2006).  
 
1.6.2 Female steroid hormones: Estrogen and progesterone signaling 
The gonadal steroid hormone estrogen (E) is commonly recognized as playing an important role 
in regulation of reproduction, maintenance of cardiovascular system, and bone density (Teede, 
2007; Brann et al. 1995; Turner et al., 1994). Over the past decade, the attention has been 
focused on the regulation of non-reproductive events in the CNS by E, such as modulation of 
synaptic plasticity, cognition, memory fine motor skills, and neuroprotection (McEwen, 2002; 
Wise et al., 2000; Acs et al., 2008). Progesterone (P) has multiple functions in the CNS and 
regulates inflammation, neurogenesis, and regeneration. Progesterone often acts in concert wit E 
to control non-reproductive brain functions such as cognition and neuroprotection (Kipp et al., 
2008; Acs et al., 2008). Estrogen and progesterone receptors are widely expressed throughout the 
brain with no restriction to a specific cell type (Kuiper et al., 1997; Quadros et al., 2007). 
Progesterone elicits its effect through progesterone receptors which similar to estrogen receptors 
have classically been described as nuclear transcription factors. After binding of the ligand to the 
native receptor and receptor homo-dimerization, the ligand-receptor complex translocates to the 
cell nucleus where it interacts with specific palindromic regions in the promoter region of target 
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genes. Besides that, E and P show other cell signaling mechanisms including interaction with 
memebrane-associated receptors and stimulation of intracellular signaling cascades (Figure 4) 
(Evans, 1988; Landers and Spelsberg, 1992; Hurn and Macrae, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cellular signaling and transduction mechanisms of steroid hormones 
Classical signaling (H) occurs through nuclear receptors that act as a ligand-activated transcription factor 
(RH), a protein complex that binds to a hormone-responsive element (HRE) within genomic DNA and 
regulates transcription of mRNA and cognate protein expression. The result is an enhanced or suppressed 
efficiency of gene transcription. Though, steroid activation of plasma membrane hormone receptors and 
downstream intracellular signaling has been demonstrated as well. In addition, steroids have non-cell 
type-specific actions, such as acting as a radical scavenger (modified from Hurn and Macrae, 2000). 
 
1.7 Nuclear hormones as modulator of neuroinflammation 
 
1.7.1 Retinoic Acid 
Anti-inflammatory effects of RA effects have already been described by Orfanos and Bauer 
(1983). They demonstrated that the oral administration of retinoids had an effect on dermal 
inflammation and reduced increased skin temperature. Retinoic acid has been shown to exert an 
immunomodulatory and anti-inflammatory role in various cell types (Datta et al., 2001; Kim et 
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al., 2004). Recent studies propose that the inhibition of NF-κB translocation and suppression of 
JAK/STAT pathways are responsible for the anti-inflammatory action of RA (Choi et al., 2005; 
Dheen et al., 2005). Different neuronal populations, including motor neurons in the spinal cord, 
hippocampal cells, and sensory neurons in the dorsal root ganglion (DRG) express RARs (Krezel 
et al., 1999). After spinal cord contusion, activated microglia/macrophages and neurons show a 
translocation of RARα, RXRα and RXRβ from the cytosol to the nucleus. High synthetic 
enzyme activity of RA metabolism and RAR translocation correlates well with improved 
behavioral performance one week after injury (Schrage et al., 2006). Retinoic acid has been 
shown to be protective in hydrogen peroxide and staurosporine induced apoptosis (Ahlemeyer et 
al., 2000; Xu et al., 2002). In hippocampal neurons, RA reduced neuronal ROS content by 
inducing SOD-1 and SOD-2 expression (Ahlemeyer et al., 2001). Retinoic acid was found to 
down-regulate transcriptional activity of NF-κB and the expression of numerous cytokines 
including IL1-α, IL1-β, IL-6, and TNF-α in vitro (Mey 2006, 2001). It has been shown that RA 
induced the release of NGF from rat cortical astrocytes (Ahlemeyer et al., 2000). Given that brain 
inflammation is a risk factor of neurodegenerative disease, the anti-inflammatory effect of RA 
may offer a novel therapeutic alternative for the treatment of neurological disorders, such as AD, 
PD, and ischemic injury. 
 
1.7.2 Estrogen and progesterone 
In the last decade, the capacity of E and P to protect against neural cell death has been endorsed, 
as exemplified by in vitro and in vivo models of neurodegeneration (Goodman et al., 1996; 
Singer et al. 1996; Bebo et al., 2001).This beneficial effect can be elucidated by their 
neurotrophic and anti-inflammatory potential. Estrogen and P were shown to modulate the 
synthesis of growth factors, such as glial-derived neurotrophic factor (GDNF) and insulin-like 
growth factor-1 (IGF-1), in neurons and astroglia (Cardona-Gómez et al., 2000; Ivanova et al., 
2002; Kaur et al., 2007). In hippocampal neurons, E and P reduced neuronal vulnerability to 
glutamate, FeSO4, and Aβ toxicity (Goodman et al., 1996). Estradiol protects neurons against 
cell apoptosis by regulating the expression of anti- and pro-apoptotic proteins. Several of the 
known anti-apoptotic genes, such as Bcl-2 and Bcl-XL, are transcriptionally activated by the 
hormone (Garcia-Segura et al., 1998). Progesterone reduced cell death in an acute model of 
global ischemia (Cervantes et al., 2002). In addition; P was protective against excitotoxicity 
insult and facilitated morphological and functional recovery during spinal cord degeneration 
(Gonzalez Deniselle et al., 2002; Gonzalez Deniselle et al., 2002). The possibility of selective 
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modulation of inflammation by E and P may be an important tool in the prevention of 
neuroinflammatory diseases.  
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2. SCOPE OF THE STUDY 
In the last decade, neuroscience research has shifted the restricted view that glial cells are just 
supportive for neurons towards the concept that glial cells may actively play a key role during 
ethiology, pathogenesis, and disease progression of neurological and neurodegenerative 
disorders. The realization of the importance of astroglial cells for these pathological processes 
suggests that astrocytes might be promising therapeutic targets. Since astrocytes regulate the 
environment for neurons and provide them with growth factors, deficits in the activity of 
astrocytes will affect neuronal excitability and function. During pathological processes, 
inflammatory cytokines, chemokines, and prostanoids released by astrocytes can directly be 
harmful for neurons. As highlighted in the introduction, the pro- and anti-inflammatory potential 
of astrocytes is still poorly understood.  
A well characterized model for glial activation in vitro is the application of LPS to primary 
astrocyte cultures derived from the neonatal rodent brain.  
In the first part of my PhD thesis, the capacity of astrocytes to respond to LPS-induced 
inflammation was investigated focusing on the synthesis, metabolism, and release of pro-
inflammatory cytokines and prostanoids. The expression pattern of enzymes responsible for 
PGE2 production and degradation was analyzed in detail.  
The second part of the study was concerned with the immune-modulatory effects of sex steroids 
and RA on LPS-induced cytokine PGE2 synthesis.  
This work was carried out in close collaboration with Dr. Eric Kampmann from the Institute of 
Biology II and Dr. Markus Kipp from the Institute of Neuroanatomy of the RWTH Aachen. 
 
1. Characterization of the inflammatory responses of murine primary astrocytes in vitro 
• LPS-induced expression of pro-inflammatory cytokines and enzymes of prostanoid 
metabolism in cortical astrocytes 
• PGE2 release and degradation in cultured cortical astrocytes 
• Region-specific cytokine synthesis in the brain in response to LPS in cultured cortical and 
mesencephalic astrocytes 
 
2. Analyzing the effect of sex steroids and retinoic acid on inflammatory processes in 
primary astrocytes  
• Regulation of basal prostanoid metabolism by RA 
• Immunomodulatory properties of RA on COX-2 expression and PGE2 release 
• LPS-provoked TNF-α and IL-18 production in cortical and mesencephalic astrocytes 
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3. MATERIAL AND METHODS 
 
3.1 Primary astrocyte culture 
Primary mesencephalic and cortical astrocytes were prepared from 1-4 days old Balb/c mice 
(Harlan Winkelmann GmBH, Germany) as previously described in detail (Pawlak and Beyer, 
2005; Kipp et al., 2007). Briefly, cerebral cortices and the midbrain were dissected, meninges 
removed and dispersed in Dulbecco’s phosphate-buffered saline containing 1% trypsin and 
0.02% EDTA, filtered through a 50  μm nylon mesh, and centrifuged at 400 g for 5 min. Cells 
were resuspended in Dulbecco's modified Eagle's medium (Invitrogen, Germany) containing 
20% heat-inactivated fetal calf serum (PAA, Austria), penicillin/streptomycin (0.5%, Invitrogen, 
Germany), and fungizone (0.1%, Invitrogen, Germany). Finally, cells were seeded in 100 mm 
plates coated with poly-DL-ornithine (Sigma, Germany) at a density of 1-2 x 106 cells/cm2. 
Astrocytes were grown at 37° C in a humidified incubator with 5% CO2. Medium was replaced 
every third day. Upon reaching confluency, cells were trypsinized and replated at a lower 
density. This procedure was repeated twice. The resulting final astroglia culture is characterized 
by > 95% homogeneity of GFAP-positive cells and no microglial or neuronal contamination 
(Pawlak and Beyer, 2005) 
 
3.2 Treatment of cell culture 
Astrocytes were used for experiments after the third replating and before reaching confluency. 
Before starting treatments, astrocytes were kept for 48 h under serum-free conditions with 
neurobasal medium (NBM, Invitrogen, Germany) supplemented with 1% glutamine, 0.2% B27 
(Invitrogen, Germany), penicillin/streptomycin (0.5%), and fungizone (0.1%) for 48h. NS-398 (a 
specific COX-2- inhibitor; Cayman Chemical,  
USA) and dexamethasone (DEX) (Sigma, Germany) were dissolved in ethanol and further 
diluted in NBM to obtain final concentrations in cultures of 10 μM NS-398, 100 nM DEX, and 
of 0.1 % solvent. Cells were exposed to 100 ng/ml Escherichia coli LPS (Sigma, Germany) for 
4-12h. This dose was found in previous experiments to be most effective in inducing cytokine 
expression by astrocytes (Kipp et al., 2007).  
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3.3 Affymetrix Gene Chip Array 
After LPS-treatment, total RNA sample collection and generation of biotinylated complementary 
RNA probes was carried out essentially as described in the Affymetrix GeneChip® Expression 
Analysis Technical Manual (Affymetrix, Santa Clara, CA, USA). In brief, each 3.6 µg of total 
RNA was reverse transcribed into double-stranded cDNA using HPLC-purified T7-(dt) 24 
primers and the GeneChip® Expression 3´ Amplification one-Cycle Target Labeling and Control 
Reagents-Kit (Affymetrix, Santa Clara, CA, USA). Subsequently, the purified double-stranded 
cDNA was used as a template to synthesize biotinylated complementary RNA probes. Each 
sample was hybridized to an Affymetrix GeneChip® Mouse Genome 430 2.0 Array (16 h at 
45°C and 60 rpm) representing approximately 34.000 well-characterized mouse genes. After 
washing and staining, the probe arrays were scanned using the GeneChip® Scanner 3000 
(Affymetrix, Santa Clara, CA, USA). Two independent experiments were performed under 
identical conditions. The microarray expression analysis and comparison were undertaken using 
Bioconductor1 packages under R2 background correction (Gentleman et al., 2004). 
Normalization was performed using the GCRMA algorithm Affymetrix Microarray Suite MAS 
5.0 software was used to make detective calls for every probe set. Selected genes whose 
expression levels differed by at least a factor of 2 (up-regulation) or 0.5 (down-regulation) in 
both experiments were further investigated by real-time RT-PCR. 
 
3.4 Quantitative RT-PCR 
Gene expression of enzymes was measured using the Light Cycler technology (Roche, Germany) 
or iCycler technology (Biorad, Germany) and a standardized protocol as described previously 
(Kampmann and Mey, 2007; Kampmann et al., 2007). Isolation of total RNA was performed 
with PeqGOLD (Peqlab, Germany). RNA concentration and purity were assessed using OD260 
and OD260/OD280 ratio, respectively, and reverse transcribed using a Promega M-MLV RT- kit, 
hexanucleotide primers (Roche, Germany) with calculated concentrations of 1 μg total RNA. 
After reverse transcription the cDNA was diluted 1:10. Reactions were carried out in a 10 µl 
volume with the QuantiTect kit (Qiagen, Germany) containing 5 µl Qiagen PCR master mix 
(including Sybr Green I, hotStarTaq DNA-polymerase, buffer, and MgCl2), 0.5 µl of each primer 
(10 µM stock), 2 µl nuclease-free water, and 2 μl of cDNA sample. The experimental protocol 
consisted of 10-15 min enzyme activation at 95°C, 40 cycles of 15 s denaturation at 94°C, 20 s 
annealing at individual temperatures, 20 s amplification at 72 °C, and 5 s fluorescence 
measurement at 78°C. Primers for the following enzymes were used: HPRT, cPLA2, COX-1, 
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COX-2, PTGES, HPGD, ALOX5, ALOXap, TNF-α, IL-18 and IL-6. Relative quantification was 
performed using the VCt method which results in ratios between target genes and a housekeeping 
reference gene (HPRT). As the validity of this method critically depends on the constant 
expression of the housekeeping gene, we analyzed the gene expression ratios of HPRT as well as 
the total RNA content in each sample at identical experimental conditions (not shown). In each 
run, external standard curves were generated by several fold dilutions of target genes. The 
concentration of the target genes was calculated using the second derivative maximum algorithm 
of the LightCycler software and crossing point analysis of log/linear plots of fluorescence/cycle 
number. Finally, data were expressed as the ratio of the amount each transcript versus the 
concentration of HPRT. Melting curves and gel electrophoresis of the PCR products were 
routinely performed to determine the specificity of the PCR reaction. 
 
3.5 SDS- PAGE and Western blot 
For immunoblotting, astrocytes were homogenized on ice in 50 mM Tris–HCl (pH 7.4) 
hypotonic buffer with 1 mM EDTA, 1% Nonidet P-40 (Igepal CA-630, Sigma), and protease 
inhibitors 1 mM phenylmethylsulfonyl fluoride, 1 μM leupeptin, and 1% aprotinin. After 15-min 
centrifugation at 12 000 g at 4°C, protein contents of the extracts were measured with the 
bicinchoninic acid assay (Sigma). Samples were separated with discontinuous sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis, 2.5μg/slot, and transferred onto a nitrocellulose 
membrane. Protein transfer and equal loading were checked with Ponceau-S staining of the blots. 
Rabbit antisera were directed against COX-2 (diluted 1:2000, 160106; Cayman Chemical), actin 
(1:5000, A2066; Sigma), and a goat anti-serum was used against COX-1 (1:500, sc1754; Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). Indirect immunodetection was based on peroxidase-
conjugated secondary antibodies (goat anti-rabbit, donkey anti-goat, both 1:5000; Sigma) and the 
enhanced chemiluminescence method (Amersham Biosciences Europe, Freiburg, Germany) 
according to standard protocol. For semi-quantitative evaluation of protein expression X-ray 
films were exposed from 30 s to 20 min to determine the linear range of the signal, and signal 
intensities were evaluated with a digital image analysis system (LTF, Wasserburg, Germany). 
COX-1 and COX-2 immunoreactivity signals were normalized to the actin signals measured in 
the same blots after stripping. 
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3.6 TNF-α, IL-6 and PGE2 Immunoassay 
The amount of TNF-α and IL-6 was quantified by commercial available ELISA kits (R&D 
Systems, Invitrogen). A polyclonal antibody specific for TNF-α/IL-6 has been pre-coated onto a 
microplate. Cell culture supernatants are pipetted into the wells and TNF-α/IL-6 is bound by the 
antibody. After washing away unbound substances, an enzyme-linked polyclonal antibody 
specific for mouse TNF-α/IL-6 is added to the wells. Following a wash step to remove unbound 
antibody-enzyme reagent, a substrate solution is added to the wells. The enzyme reaction yields a 
blue product that turns yellow when the Stop Solution is added. The intensity of the color was 
measured at a wavelength of 450nm. The sample values are then read off the standard curve. 
PGE2 release into the supernatant was measured with a PGE2 enzyme-immunosorbent assay 
(EIA) kit from Cayman chemical (Cayman Chemical, USA) according to the manufacturer’s 
instruction. Samples of the culture medium were diluted with NBM (1:5 and 1:10) and measured 
at a wavelength of 405 nm. PGE2 levels were determined in duplicates and extrapolated from 
routine standard curves. Data are expressed as pg/ml. 
TNF-α concentration in the supernatant was calculated by interpolation from standard curves 
provided by the manufacturers. Finally, data were expressed as the ratio of the amount of     
TNF-α  from 10-6cells. Sample analysis was performed in triplicates in three independent 
experiments. 
 
3.7 Antibody Array 
Quantitative assessment of a selected subset of cytokines was performed using a commercially 
available array-based technology, RayBioTM Cytokine Angiogenesis Antibody Array 
(RayBiotech Inc., Atlanta, USA). Array membranes were incubated with 2 ml of Blocking Buffer 
for 30 min at room temperature. After blocking, 2 ml of cell culture supernatant was added to the 
membranes followed by an overnight incubation at 4°C. After a washing step, 1 ml of diluted 
biotin-conjugated antibodies was added. Membranes were incubated at room temperature for 1-2 
hours. After a second washing step, membranes were incubated with 2 ml of HRP-conjugated 
streptavidin. Bound cytokines were visualized with Detection Buffer, according to the 
manufacturer’s protocol. The sensitivity of the cytokine antibody array was 1 pg/ml for each of 
the cytokine. Densitometrical quantification (OD measurement) was performed with an 
AlphaImager system (Alpha Innotech, USA). 
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3.8 LDH assay 
Astrocyte cell death was assessed by measuring the release of lactate dehydrogenase (LDH) into 
the culture medium after treatment with LPS. To determine LDH activity 90 µl medium were 
mixed with 50µl Reaction mixture from Roche Cytotoxicity detection kit and incubated for 60 
min in the absence of light. The conversion of lactate and NAD+ to pyruvate and NADH results 
in a red formazan product, which was measured by Microplate ELISA reader (MWG-Biotech) at 
a wavelength of 490nm. LDH release was percental normalized in accordance to maximal LDH 
release after treatment with 1% Trizol. 
 
3.9 Life death assay 
The LIFE/DEADTM viability/cytotoxicity kit for mammalian cells (Molecular Probes) was used 
for determination of cell survival. This method distinguishes living cells by the presence of 
ubiquitous intracellular esterase activity, which converts the nonfluorescent cell-permeant calcein 
AM to the green fluorescing calcein. EthD-1 the second dye of the kit enters only cells with 
damaged membranes and produces a red fluorescence in dead cells upon binding to nucleic acids. 
Treated astrocytes grown on poly-l-lysin coated cover slips were incubated with both dyes 
(concentration). After 30 min. cultures were microscopically evaluated and photographed with a 
Zeiss Axiophot epifluorescence microscope coupled to an on-line digital camera (Axiovision 
software).. To determine the percentage of dead cells for each culture living and dead cells were 
counted in six different regions, which were regularly distributed on each cover slip. 
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4.  Expression of enzymes involved in the prostanoid metabolism by cortical astrocytes 
after LPS-induced inflammation 
 
4.1 Abstract 
Neuroinflammatory processes are a common epiphenomenon for a number of neurological and 
neurodegenerative diseases. Besides microglia, astrocytes are implicated in brain inflammation in 
response to harmful stimuli and pathological processes. Bacterial endotoxins can induce the 
synthesis and release of pro-inflammatory mediators, i.e. cytokines and chemokines, by astroglia. 
In this study, we have investigated the effect of LPS-treatment on the expression of enzymes of 
prostanoid synthesis and degradation in cultured mouse cortical astrocytes using an Affymetrix 
Gene Chip array, quantitative RT- PCR, and an enzyme-immunosorbent assay. LPS-treatment 
induced an up-regulation of enzymes responsible for prostaglandin E2 synthesis, a down-
regulation of enzymes which catalyze PGE2 degradation and production of pro-inflammatory 
leukotrienes. Changes in enzyme expression were accompanied by a highly significant increase 
in extracellular PGE2. Our data demonstrate that astrocytes are directly involved in the complex 
regulation of pro-inflammatory prostanoids in the CNS under pathological processes, thus being 
of potential interest as targets for therapeutical interventions. Further studies are required to 
unravel the different roles and interactions between astroglia and other cells of the brain-intrinsic 
innate immune system during inflammation. 
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4.2 Introduction 
Neuroinflammation is a complex biological process in the CNS in response to various stimuli 
such as oxidative stress, endotoxins, mechanical injury, and neurodegenerative diseases. Two 
types of inflammatory responses are known to occur in the CNS. They were classified as acute 
and chronic inflammation (Lucas et al., 2006). Neurodegenerative disorders, i.e. Alzheimer’s and 
Parkinson’s disease, and stroke are often accompanied by chronic inflammatory events. Acute 
inflammation is typically associated with ischemia or spinal cord trauma (Lucas et al., 2006). 
Most of the studies in the field of neuroinflammation focus on the role of microglia, the immune 
competent “macrophages” in the brain (Aloisi et al., 2000; Schwartz et al., 2006). Most recent 
studies, however, revealed that astrocytes are not only supportive cells for neurons (Kipp et al., 
2006; Pellerini et al., 2007) but also take actively part in the initiation and modulation of immune 
reactions in the CNS (Farina et al., 2007). Under pathological conditions, astrocytes release a 
number of pro-inflammatory cytokines, such as IL-6, TNF-α and IL1-β (Farina et al., 2007; 
Fisher et al., 2007; Kipp et al., 2007). In addition, astrocytes have the property to synthesize 
eicosanoids, including prostaglandins, thromboxanes, and leukotrienes (Tzeng et al., 2005). 
These compounds are potent paracrine and autocrine mediators involved in pathophysiological 
processes in the brain (O’Banion and Finch, 1996; Minghetti, 2004). The first step in eicosanoid 
synthesis is mediated by the enzyme phospholipase A2 (PLA2) (for a schematic summary of 
eicosanoid metabolism see Fig. 4). Three PLA2 subtypes are known, including a secretory PLA2 
(sPLA2), a cytosolic PLA2 (cPLA2), and a calcium-independent PLA2 (iPLA2) (Murakami et al., 
2000; Murakami and Kudo, 2002). Both, cPLA2 and sPLA2, are implicated in the regulation of 
PGE2 synthesis and -release under pathological conditions, e.g. during ischemia and after 
exposure to various neurotoxins (Murakami and Kudo, 2002; Sun et al., 2004). The conversion 
of arachidonic acid to PGH2, the precursor for prostaglandins and thromboxanes is catalyzed by 
cyclooxygenases (COX). In the nervous system, the two known COX isoforms, COX-1 and 
COX-2, are encoded by different genes. COX-1 is constitutively expressed and thought to be 
barely regulated. This enzyme is required for the synthesis of physiological levels of 
prostaglandins (Yermakova and O´Banion, 2000). In contrast, COX-2 is highly regulated under 
inflammatory conditions and responsible for the production of pro-inflammatory prostaglandins, 
including PGE2, at high local levels (Samad et al., 2001; Phillis et al., 2006). The inhibition of 
COX-2 is neuroprotective in animal models for ischemia and amyotrophic lateral sclerosis 
(Iadecola et al., 2001; Klivenyi et al, 2004). A COX-1 splice variant (putative COX-3) was 
recently detected in murine tissues and glia cells (Shaftel et al., 2003, Kis et al., 2006). COX-3 
protein reveals a different amino acid sequence compared to COX-1/2 and appears not to be 
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involved in PGE2 synthesis under pathological conditions (Kis et al., 2006). The degradation of 
PGE2 and other prostanoids is mediated by 15-hydroxy prostaglandin dehydrogenase (HPGD) 
which converts PGE2 to inactive metabolites (Ivanov and Romanovsky, 2004). Arachidonic acid 
is also a substrate for the enzyme 5-lipoxygenase (ALOX-5) which forms the pro-inflammatory 
leukotrienes LTB4 and LTC4 (Farooqui et al., 2007). 
Figure 4. Schematic diagram of major routes of prostanoid metabolism. PLA2 releases arachidonic acid 
from glycerophospholipids which, in turn, is converted by cyclooxygenase 1 (COX-1) and 
cyclooxygenase 2 (COX-2) to prostaglandin H2 (PGH2). PGH2 is the precursor for all prostaglandins and 
thromboxanes. The microsomal prostaglandin E synthase (PTGES) generates PGE2. PGE2 is further 
degraded rapidly by 15-hydroxy prostaglandin dehydrogenase (HPGD). Alternatively, arachidonic acid is 
also a substrate for lipoxygenases (ALOX-5, 12, and 15), which catalyze the synthesis of pro-
inflammatory leukotrienes and lipoxins. The enzymes marked in bold were mainly part of this study. 
 
The contribution of astroglial cells to brain prostanoid metabolism has been analyzed in few 
experimental studies. No detailed information is available on the regulation of prostanoid 
metabolism in astrocytes after inflammatory processes. Therefore, we have mimicked a bacterial 
inflammation in cultured cortical astrocytes by treatment with the endotoxin lipopolysaccharide 
(LPS) (Pistritto et al., 1999). The molecular and cellular mechanisms of LPS-mediated responses 
of the innate immune system are well known (Palsson-McDermott and O’Neill, 2004). Briefly, 
circulating LPS binds to the LPS binding-protein (LBP) and CD-14. The CD-14/LPS complex 
reacts with the Toll-like receptor 4/MD-2 complex which is necessary for LPS-induced signal 
transduction. Myd88 and MAL are further adapter proteins for TLR-4 signaling. Concomitantly, 
we have studied the expression and regulation of enzymes involved in different pathways of 
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prostanoid metabolism by Affymetrix Gene Chip arrays, quantitative RT-PCR, and measurement 
of PGE2 synthesis. 
 
4.3 Material and Methods 
 
4.3.1 Primary cultures of cortical astrocytes 
Primary cortical astrocytes were prepared from 1-4 days old Balb/c mice (Harlan Winkelmann 
GmBH, Germany) as previously described in detail (Pawlak and Beyer, 2005; Kipp et al., 2007). 
Upon reaching confluency, cells were trypsinized and replated at a lower density. This procedure 
was repeated twice. The resulting final astroglia culture is characterized by > 95% homogeneity 
of GFAP-positive cells and no microglial or neuronal contamination (Pawlak and Beyer, 2005) 
 
4.3.2 Cell culture treatment 
Astrocytes were used for experiments after the third replating and before reaching confluency. 
Before starting treatments, astrocytes were kept for 48 h under serum-free conditions with 
neurobasal medium (NBM, Invitrogen, Germany) supplemented with 1% glutamine, 0.2% B27 
(Invitrogen, Germany), penicillin/streptomycin (0.5%), and fungizone (0.1%) for 48h. NS-398 (a 
specific COX-2- inhibitor; Cayman Chemical, USA) and dexamethasone (DEX) (Sigma, 
Germany) were dissolved in ethanol and further diluted in NBM to obtain final concentrations in 
cultures of 10 μM NS-398, 100 nM DEX, and of 0.1 % solvent. Cells were exposed to 100 ng/ml 
Escherichia coli LPS (Sigma, Germany) for 12 h. This dose was found in previous experiments 
to be most effective in inducing cytokine expression by astrocytes (Kipp et al., 2007). 
Preliminary experiments have shown that this LPS dose was most effective in inducing PGE2 
synthesis in astroglia (not shown).  
 
4.3.3 Affymetrix Gene Chip array  
After LPS-treatment, total RNA sample collection and generation of biotinylated complementary 
RNA probes was carried out essentially as described in the Affymetrix GeneChip® Expression 
Analysis Technical Manual (Affymetrix, Santa Clara, CA, USA). Selected genes whose 
expression levels differed by at least a factor of 2 (up-regulation) or 0.5 (down-regulation) in 
both experiments were further investigated by real-time RT-PCR. 
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4.3.4 Quantitative RT-PCR 
Gene expression of enzymes was measured using the Light Cycler technology (Roche, Germany) 
and a standardized protocol as described previously (Kampmann and Mey, 2007; Kampmann et 
al., 2007). Primers for the following enzymes were used: HPRT, cPLA2, COX-1, COX2, PTGES, 
HPGD (see Table 1). Relative quantification was performed using the VCt method which results 
in ratios between target genes and a housekeeping reference gene (HPRT). Finally, data were 
expressed as the ratio of the amount each transcript versus the concentration of HPRT. Melting 
curves and gel electrophoresis of the PCR products were routinely performed to determine the 
specificity of the PCR reaction.  
 
Table 1. Primer sequences used for quantitative real-time RT-PCR 
 
primers sequences 
     cPLA2 sense 
           antisense 
5’-AGG CAC AGC TAC ATT CCC TG-3’ 
5’-CAT GCT GAA CCG TAG GTC TGG-3’ 
    COX-1 sense 
           antisense 
5’-TGT TCA GCT TCT GGC CCA ACA GCT-3’ 
5’-AGC GCA TCA ACA CGG ACG CCT GTT-
    COX-2 sense 
           antisense 
5’-CCC CCA CAG TCA AAG ACA CT-3’ 
5’-CTC ATC ACC CCA CTC AGG AT-3’ 
    PTGES sense 
           antisense 
5’-AGA TGA GGC TGC GGA AGA AG-3’ 
5’-CCT GTG AGG ACA ACG AGG AA-3’ 
     HPGD sense 
           antisense 
5’-GTT TCT GTT ATC GGT GGG ACC T-3’ 
5’-GGA TTC AAG GAT GGG TGT GTC-3’ 
  ALOX-5 sense 
           antisense 
5’-GAT TCC GCA AGA ACC TGG AG-3’ 
5’-CAG GAA GAT CGA CCC AGA GC-3’ 
      HPRT sense 
antisense
5’-GCT GGT GAA AAG GAC CTC T-3’   
5’-CAC AGG ACT AGA ACA CCT GC-3’
 
 
 
 
 
 
 
 
 
 
 
For abbreviations see text. 
 
4.3.5 ELISA for PGE2 
PGE2 release into the supernatant was measured with a PGE2 enzyme-immunosorbent assay 
(EIA) kit from Cayman chemical (Cayman Chemical, USA) according to the manufacturer’s 
instruction. Samples of the culture medium were diluted with NBM and measured at a 
wavelength of 405 nm. PGE2 levels were determined in duplicates and extrapolated from routine 
standard curves. Data are expressed as pg/ml.  
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4.3.6 Statistical analysis 
A total of nine independent experiments were performed each consisting of 2-5 wells for each 
treatment/condition. For each independent culture, cortical tissue from five neonatal mice was 
pooled. Time-course experiments were tested in duplicate experiments. For quantitative studies 
on gene expression, at least four independent experiments were made for each set of data. The 
EIA experiments were replicated in three independent experiments. Unlike otherwise stated, data 
are expressed as means  +/- SEM. Statistical significance was evaluated with ANOVA test of 
variance followed by Mann-Whitney U test or t-test with p < 0.05 considered to be significant. 
Analysis with the Affymetrix GeneChip Array was performed for two independent samples of 
the control condition and two samples after LPS-treatment. 
 
4.4 Results 
This in vitro study was conceived to obtain information about the role of astrocytes in prostanoid 
metabolism and its regulation by LPS, which mimics bacteria-induced inflammatory processes in 
this cell type (Palsson-McDermott and O’Neill, 2004). In a first set of experiments, we have 
analyzed gene expression profiles enzymes involved in prostanoid metabolism in cultured 
cortical astrocytes under control conditions and LPS challenge using an Affymetrix Gene Chip 
array (Table 2). This study first revealed that astrocytes express all types of LPS receptive 
proteins such as MD-2, CD14, Toll-like receptor-4, and MYD88. Interestingly, LPS boosted the 
expression of CD14 and MYD88 15- and 8-fold, respectively. With respect to prostanoid-
metabolizing enzymes, we found all major classes of enzymes to be present in untreated 
astrocytes, although to a low-moderate level and with a specific subset of isoforms. Prostanoid-
metabolizing enzymes (isoforms) not listed in Table 2 were not detectable by the Affymetrix 
Gene Chip array. This specifically applies to the inducible form of PLA (iPLA), which is not 
expressed in control and LPS-exposed astrocytes. In addition to the above mentioned proteins, 
the array analysis revealed that astrocytes contain different types of prostaglandin receptors, e.g. 
PTGER-2, -4, and PTGIR whereas the other receptor forms were absent. Again, it became 
evident that LPS increased levels of PTGIR about 10-fold leaving the other receptors unchanged 
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Table 2. Regulation of enzymes involved in prostanoid metabolism in cortical astrocytes analyzed by 
Affymetrix Gene Chip array. 
Data were obtained from two independent experiments 
and are given as means. Enzymes marked in bold were 
identified to differ from controls by more than 50% 
and further used for quantitative qRT-PCR analysis. 
For experimental procedures see Materials and 
methods (Affymetrix Gene Chip assay). For 
abbreviations see text. 
 
 
 
 
 
 
 
 
 
 
 
In the second part of the study, we have quantitatively analyzed the expression profiles of those 
prostanoid-metabolizing enzymes which exhibited LPS-dependent differences (> 2 and/or < 0.2) 
compared to controls, except for TBXAS which was not further investigated because it regulates 
thromboxane pathways. These proteins, marked in bold in Table 2, are in particular cPLA2, 
COX-1, COX-2, PTGES, ALOX-5, and HPGD. Treatment with LPS significantly stimulated the 
expression levels of three major enzymes implicated in PGE2 synthesis, i.e. cPLA2, COX-2, and 
PTGES (Figures 5 and 6). COX-2 and PTGES mRNA levels were up to 800-fold and 100-fold 
higher compared to controls, respectively; cPLA2 mRNA was increased by a factor of 4-6. In 
contrast, enzymes which are necessary for PGE2 degradation or leading to other metabolic 
pathways, e.g. ALOX-5 and HPGD, were significantly decreased after LPS. This was also true 
for the expression of COX-1 mRNA. 
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Figure 5. The effect of LPS-treatment on the expression pattern of enzymes involved in prostanoid 
metabolism. Quantification of mRNAs was performed by real-time RT-PCR. LPS-treatment (12 h, 100 
ng/ml) of cortical astrocytes significantly reduced mRNA levels of COX-1, HPGD, and ALOX5, whereas 
the expression of COX-2, cPLA2, and PTGES was stimulated. Control © cultures were set to 1, and data 
from LPS-exposed cultures are given as -fold changes relative to C. Data were normalized against the 
housekeeping gene HPRT for each sample and represent means +/- SEM from at least seven independent 
cultures. Data are plotted logarithmically. Mann-Whitney U test, *p < 0.01 vs. control, **p < 0.001 vs. 
control. 
 
The control of COX-1 and COX-2 represents the major rate-limiting step in PGE2 synthesis. 
Therefore, we have particularly focused on the expression pattern of these enzymes and 
attempted to correlate PGE2 production and release into the extracellular space with COX-1 and 
2 expression profiles. Figure 3 summarizes these data and shows that there exists a steady 
increase of LPS-induced COX-2 expression with a maximum after 12 h. After 24 h, it appears 
that expression of COX-2 declines again (Figure 6A). This profile is in striking contrast to COX-
1, whose expression decrements over time until 12 h and recovers thereafter (Figure 6B). The 
analysis of PGE2 levels in the culture supernatant by a highly specific immunosorbent assay 
showed that (i) under control conditions, very low levels of PGE2 were detectable and (ii) after 9 
h of LPS-treatment PGE2, levels had significantly increased and continued to rise at least until 12 
h. Overall, we measured an increase of PGE2 levels from approx. 20 pg/ml in controls to approx. 
600 pg/ml after 12 h LPS (Figure 6C). 
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Figure 6. Time-course of LPS-induced (12 h, 100 ng/ml) stimulation of COX-2 (A) and COX-1 (B) 
mRNA expression, and production of PGE2 (C) in cortical astrocytes. Cells were incubated with 100 
ng/ml LPS for different time intervals. Specific mRNAs were quantified by real-time RT-PCR. 
Expression values for COX-1/COX-2 were normalized against the housekeeping gene HPRT. Values 
from untreated controls (C) were set to 1 (in A and B). (C) The amount of PGE2 (ng/ml) in the culture 
supernatant was measured by EIA. In A and B, data are plotted logarithmically. Data represent means +/- 
SD from three experiments. 
 
Since the glucocorticoid dexamethasone is well-known to interfere with basal PGE2 synthesis 
and its regulation, we conducted experiments where astrocytes were simultaneously exposed to 
LPS and dexamethasone. In this survey, we could demonstrate that dexamethasone significantly 
counteracted the LPS-mediated induction of cPLA2-, COX-2-, and to a lesser extent, PTGES and 
ALOX-5 expression (only the data for cPLA2, COX-2 and PTGES are given in Figure 7A). This 
effect was complete (cPLA2) or only partial (COX-2, PTGES, ALOX-5). By contrast, the LPS-
dependent decrease of HPGD and COX-1 by LPS (see also Figures 6 and 7) was not antagonized 
by dexamethasone (only the data for HPGD are shown). Overall, we found that dexamethasone 
treatment almost completely inhibited PGE2 synthesis similar to NS-398 which is known as a 
strong inhibitor of COX-2 (Figure 7B). The application of dexamethasone alone to control 
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cultures did neither affect the expression of the six enzymes studied (see Figure 5) involved in 
prostanoid metabolism nor PGE2 synthesis rates (data not shown).  
 
 
 
Figure 7. The effect of dexamethasone (DEX) and the COX-2 inhibitor NS-398 on LPS-mediated 
regulation of enzymes involved in prostanoid metabolism as well as on PGE2 production in cortical 
astrocytes. (A) Real-time RT-PCR analysis. Values of individual mRNAs (LPS-treatment, 12 h, 100 
ng/ml) were set to 1, and the corresponding mRNA levels (DEX treatment) were calculated as fractions of 
the LPS-induced level. Data are plotted logarithmically. Note that the LPS-induction of cPLA2, COX-2, 
and PTGES expression was completely (cPLA2), or partially (COX-2, PTGES) prevented by DEX-
treatment, whereas the effect on HPGD was not affected. (B) NS-398, a specific COX-2 inhibitor, and 
DEX (1 μM) completely inhibited PGE2 synthesis. Data represent means +/- SEM from 3-4 independent 
experiments. Mann-Whitney U test, **p < 0.01 vs. LPS, *p < 0.001 vs. LPS. 
 
4.5 Discussion 
This study intended to elucidate the potential and contribution of mouse cortical astrocytes to 
brain prostanoid metabolism, and the molecular mechanisms of LPS-action on this metabolic 
pathway. Primary astroglial cultures were chosen as a valid in vitro model. This system consists 
of a relatively homogeneous cell population without neuronal and microglial contamination and 
offers the possibility to manipulate cells under controlled conditions (Pawlak et al., 2005; 
Kampmann et al., 2007; Kipp et al., 2007). The endotoxin LPS was selected for cell treatment to 
mimic a bacterial infection of neural tissue (Pistritto et al., 1999; Uematsu et al., 2002). Our data 
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show that non-activated cortical astrocytes express a number of enzymes involved in PGE2 
metabolism at moderate levels but possess only a low capacity of PGE2 synthesis. This may be 
the result of low COX-2 expression even in the presence of high COX-1 expression. Astrocytes 
have previously been shown to be sensitive to LPS-stimulation (Palsson-McDermott and O’Neill, 
2004). We have confirmed and extended these data by our gene expression study which reveals 
that cortical astrocytes express all receptive proteins for signal transmission of LPS, e.g. CD14, 
MD-2, MYD88, and Toll-like receptor-4. The impact of LPS-exposure on astrocyte prostanoid 
metabolic pathways can be summarized as follows: Enzymes which are essential for PGE2 
synthesis, mainly cPLA2 (precisely, the cPLA2 group 4A) and COX-2, were massively increased 
after LPS-application, whereas degrading enzymes (ALOX-5 and HPGD) were inhibited. The 
ultimate result is a high PGE2-production rate and -release into the extracellular space. Based on 
the Affymetrix data, a number of other prostanoid-metabolizing enzymes/isoforms were not 
detectable under control and experimental conditions. These were in particular iPLA2 and 
different sPLA2 subgroups. 
Microglia and astroglia act as innate immune cells in the inflamed brain. Both cell types 
contribute to the onset of inflammation in different brain diseases by producing deleterious pro-
inflammatory mediators such as reactive oxygen species, interleukins, chemokines, and 
prostanoids (Gebicke-Haerter 2001; Tzeng et al., 2005; Kipp et al. 2007). As a consequence, glial 
cells, and particularly microglia, are believed to play an active role in brain inflammatory, 
immune, and finally degenerative processes. Depending on the magnitude of glial reaction, on 
the type of stimulus, and on the concurrence of other local factors, glial cells can contribute to 
host defense and repair, or to the establishment and maintenance of neural damage. Some of the 
effects of glial cells can be ascribed to pro-inflammatory cytokines and prostanoids (Minghetti, 
2004; Minghetti and Levi, 1998). Prostanoids derive from arachidonic acid through the PLA2 and 
cyclooxygenase pathway. Cyclooxygenases (COX-1 and 2) convert arachidonic acid to PGH2 
which serves as main precursor for all further prostanoids. Thus, PLA2 and COX represent the 
key enzymes in prostanoid synthesis. COX-2 has emerged as a major player in pro-inflammatory 
reactions in brain and peripheral tissues and is thought to be instrumental in neurodegenerative 
events of several acute and chronic diseases (Sun et al., 2004). This isoform is up-regulated, for 
instance, in PD (Teismann et al., 2003), AD (Yermakova and O’Banion, 2000), amyotrophic 
lateral sclerosis (Pompl et al., 2003; Minghetti, 2004), and stroke (Institoris et al., 2007). In line 
with a neurotoxic role for PGE2 (and therefore COX-2 activation) are data which reveal 
neuroprotection under pathological premises in COX-2 deficient mice (Iadecola et al., 2001). In 
contrast to COX-2, the other isoform appears to be constitutively expressed and is responsible for 
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low but physiologically relevant PGE2 production (Farooqui et al., 2007). In this context, it is 
noteworthy that PGE2 at moderate levels and under defined conditions may not only contribute to 
brain damage but rather affects and modulates neuronal function in a positive way through the 
regulation of microcirculation and synaptic function (Haydon and Carmignoto, 2006). Besides 
the well-defined role of microglia during inflammatory processes, it was already established in 
1988 that astrocytes can synthesize eicosanoids (Murphy et al., 1988). Bacterial endotoxins were 
further demonstrated to induce COX-2 expression and PGE2 production in hypothalamic 
astrocytes through the activation of nuclear factor kappa B (Pistritto et al., 1999). Our data 
support these findings by demonstrating a rapid and massive induction of COX-2 expression 
after LPS in cortical astrocytes. In addition, attention is to be paid to the complexity of enzymatic 
pathways embedded in prostanoid synthesis and degradation rather than focusing only on COX-2 
regulation. Unequivocally, LPS causes a multitude of cellular responses in our cell system 
including the induction of the key anabolic enzymes (cPLA2, COX-2, PTGES) and, at the same 
time, the reduction of key metabolic enzymes (ALOX-5, HPGD). As a result, LPS-exposure 
yields a deleterious increase in PGE2 production and release of >100fold within a few hours. 
Interestingly, we also observed an increased sensitivity of astrocytes for LPS and PGE2 as shown 
by an elevated expression of LPS- and PGE2 receptors. Auto-regulation of PGE2 receptors by 
PGE2 has already been reported in osteoblast (Shoji et al., 2006). Although it is speculative at 
present, an autocrine/paracrine regulation of PGE2 receptors may play a role for the coordination 
and synchronization of local astroglial PGE2 responses on the one hand, but then also may be 
necessary for a time-dependent termination of PGE2-action (Richards et al., 2002; Narumiya, 
2003; Harizi and Gualde, 2005). In addition to these observations, we detected a significant 
reduction in COX-1 expression after LPS although this enzyme is generally regarded as a 
constitutive form. However, a down-regulation of COX-1 mRNA has also been reported by 
Uematsu et al. (2002) in peritoneal macrophages after LPS administration. In support are 
findings which describe the regulation of COX-1 but not COX-2 by bradykinin in neonatal glial 
cells (Levy et al., 2007). The biological relevance of this response is, at the moment, not clear but 
might have its origin in a competition of the enzyme substrate for COX-1 and COX-2. 
Dexamethasone, which is known to inhibit inflammatory PGE2 synthesis, prevented the LPS-
induced PGE2-production in our experiments as the result of an abrogation of LPS-effects on 
cPLA2, COX-2, and PTGES expression. The LPS-induced inhibition of COX-1 and HPGD was 
not counteracted by dexamethasone. It also needs to be mentioned that basal/un-stimulated 
prostanoid metabolism by astroglia is not affected by dexamethasone. 
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Although the evidence is apparent that both types of glial cells (microglia and astroglia) 
contribute to prostanoid synthesis under inflammation in the brain, the specific roles of both cell 
types during inflammatory processes are not really understood. Astrocytes invade and proliferate 
very rapidly in injured brain areas, e.g. as a response to stroke. This occurs before microglia is 
attracted. Thus, it might be assumed that astroglia adopt the function of early and immediate 
PGE2 production. Rising levels of PGE2 not only initiate neurotoxicity (Kawano et al., 2006) but 
also govern microcirculation (Gordon et al., 2007). At the same time, pro-inflammatory 
interleukins are synthesized and released by astrocytes (Kipp et al., 2007). Later in the course of 
inflammation, this function is conferred to activated microglia. This is confirmed by data 
disclosing the importance of PGE2 acting via receptor subtype 2 for microglial activation (Jin et 
al., 2007). Thus, it is conceivable that astrocytes regulate microglial cells which, subsequently, 
carry on the regime of further regulation and balance of local immune responses. Astrocytes, in 
turn, may switch to a neuroprotective role by controlling glutamate metabolism and providing 
neuroprotective growth factors (Darlington, 2005; Takuma et al., 2004; Kampmann et al., 2007; 
Karakaya et al., 2007; Kipp et al., 2007).  
In conclusion, we have shown that LPS induced an up-regulation of several key enzymes 
responsible for prostanoid synthesis in astrocytes, whereas PGE2-degrading enzymes were 
inhibited. As a consequence, we observed a rapid and massive >100fold rise in extracellular 
PGE2. Regardless that dexamethasone only inhibited some of the LPS-effects on gene 
expression, a complete interruption of PGE2 synthesis was observed. We assume that astrocytes 
are the first innate immune cells in the brain which are activated after an acute bacterial 
inflammation and adopt the role of providing sufficient PGE2 supply, thus bridging a time period 
until microglia becomes activate. 
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5.   Anti-inflammatory effect of retinoic acid on prostaglandin synthesis in cultured cortical 
astrocytes 
 
5.1 Abstract 
Prostanoids are important mediators of inflammation and pain signaling. Although it is now well 
accepted that astrocytes participate in inflammatory reactions in the CNS, the molecular 
regulation of this activity is still largely unknown. Specifically, the regulation of prostanoid 
synthesis by this type of glia remains to be resolved. Recent evidence suggests that the 
transcriptional regulator retinoic acid (RA) is involved in regulation of the immune response. We 
have investigated the expression pattern of the enzymes that catalyze prostanoid and leukotriene 
synthesis in cultured cortical astrocytes, their stimulation by lipopolysaccharides (LPS) and their 
regulation by RA. The data indicate that astrocytes are an important source of prostaglandins 
(PGs) and that RA reduces their inflammatory biosynthesis. LPS treatment induced the 
expression of enzymes for the production of arachidonic acid and PGs but caused down-
regulation of a PG degrading enzyme and of leukotriene synthesizing enzymes that compete with 
PG synthesis. Consequently, the secretion of the PGE2 was highly increased after LPS exposure. 
RA counteracted the inflammatory regulation of cyclooxygenase (COX)-2 mRNA and protein in 
astrocytes and thereby reduced the synthesis of PGE2 by approximately 60%. In the absence of 
LPS, RA enhanced the expression of COX-1 mRNA. In conclusion, RA might be effective in 
suppressing inflammatory processes in the brain by inhibiting PG synthesis. 
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5.2 Introduction 
Pathological processes in the CNS following injury, infection or during degenerative diseases are 
usually accompanied by inflammatory reactions. Although inflammation has adaptive functions, 
e.g., elimination of pathogens, it may also be responsible for the degeneration of affected 
neurons. It is therefore a controversial issue whether the neuroinflammatory process is rather 
beneficial or detrimental with regard to the clinical outcome (Schwartz et al. 1999; Farina et al. 
2007). Whereas microglia are regarded as the most important immune-competent cells of the 
CNS, it became evident during the last decade that astrocytes are also modulators of 
inflammation (Farina et al. 2007). Reactive astrocytes produce inflammatory cytokines, including 
interleukin (IL)-1β, IL-6, interferon c, and tumor necrosis factor (TNF-α), and are therefore 
capable of both inducing and modulating immune reactions (Dong and Benveniste 2001). To 
study inflammation in vitro, cell cultures are typically stimulated with bacterial endotoxins, most 
frequently lipopolysaccharides (LPS). After binding to CD14 and toll-like receptor 4, LPS 
activates the nuclear transcription factor NF-κB, which regulates a large number of inflammatory 
genes (Li and Stark 2002). This signal sequence occurs not only in microglia but also in 
astrocytes, where it is most relevant for the course of neurodegenerative diseases and ischemia 
(Galea et al. 1996; Farina et al. 2007). In addition to their pro-inflammatory role, astrocytes are 
implicated in the formation of glial scars, which serve to limit the area of secondary 
degeneration. Astrocytes also participate in tissue regeneration, produce anti-inflammatory 
mediators and neurotrophic factors, and regulate excitotoxic extracellular glutamate (Bush et al. 
1999; Liberto et al. 2004). The repertoire of astrocytes-derived pro-inflammatory and anti-
inflammatory factors also contains prostanoids and leukotrienes. These are a family of paracrine 
and autocrine lipid mediators derived from arachidonic acid (Phillis et al. 2006; Farooqui et al. 
2007). Enzymes of prostanoid metabolism are associated with neuroinflammation and 
neurodegenerative diseases (Minghetti 2004; Sun et al. 2004). By blocking cyclooxygenases 
(COX, the key enzymes for the synthesis of prostanoids), the non-steroidal anti-inflammatory 
drugs are effective against pain and autoreactive diseases. Of two known COX genes in the brain, 
COX-1 is constitutively expressed, whereas COX-2 is highly induced upon activation with LPS. 
Although COX-2 expression occurs in certain neuronal populations as well, activated microglia 
and astrocytes are the main sources of prostaglandins (PGs) during neuroinflammation (Hirst et 
al. 1999; Yermakova and O’Banion 2000; Xu et al. 2003; Farooqui et al. 2007; Strokin et al. 
2007). Independent of COX activity, leukotrienes are synthesized from arachidonic acid by the 
lipoxygenase 5 (Alox5) enzyme (Phillis et al. 2006; Farooqui et al. 2007). Following the COX-
catalyzed oxidation of arachidonic acid, several derivates called prostanoids can be synthesized, 
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which either belong to the family of thromboxanes or of PGs. Prostanoids are thought to have 
both pro-inflammatory and anti-inflammatory effects depending on the specific molecule, the 
biological context and the receptor expression of target cells. PGE2 is one of the most prominent 
prostanoids produced by astrocytes when exposed to noxious stimuli (Kalmar et al. 2001; 
Teather et al. 2002; Xu et al. 2003). Despite the importance for inflammatory processes and a 
broad spectrum of physiological functions in the CNS, not much is known about the regulation of 
prostanoid synthesis in astrocytes (Mohri et al. 2007; Strokin et al. 2007). The transcriptional 
activator retinoic acid (RA) influences a wide range of biological processes, including 
morphogenesis and glial and neuronal cell differentiation. We suggest that RA is also involved in 
the modulation of neuroinflammatory processes by microglia and astrocytes. RA is synthesized 
from blood-derived vitamin A and controls gene activity by binding to nuclear receptors (Bastien 
and Rochette-Egly 2004). RA receptors (RAR)-α, -β, and –γ bind all-trans RA and 9-cis RA. 
Retinoid X receptors (RXR)-a, -b, and -c only bind 9-cis RA. These are heterodimeric partners of 
RAR and other nuclear receptors which then act as ligand-activated transcription factors. Among 
the various RA isomers, the only natural ligand appears to be all-trans RA. In addition to the 
direct transcriptional control, many target genes are regulated indirectly and several non-genomic 
actions of RA are also known (Blomhoff and Blomhoff 2006). Several lines of evidence suggest 
that RA is an important immune modulator with regards to T-cell selection, B-cell migration, and 
neutrophil differentiation (Na et al. 1999; Mathew and Sharma 2000). Consequently, the question 
arises whether RA signaling influences inflammation-related PG production. Such influence is 
discussed in immunology and oncology but has not been studied empirically in the context of 
glial cell physiology. As RA was shown either to enhance or to attenuate PG synthesis in 
different experimental settings (Schneider et al. 2001; Kim et al. 2004; Romero-Sandoval et al. 
2004; Song et al. 2005; Alique et al. 2007), the published findings cannot easily be extrapolated 
with respect to neuroinflammatory processes. A beneficial effect of RA on the course of 
neuroinflammation has been postulated (Racke et al. 1995; Choi et al. 2005; Dheen et al. 2005; 
Mey 2006). We therefore decided to investigate the influence of RA on PG metabolism in 
cultured cortical astrocytes. 
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5.3 Material and Methods 
 
5.3.1 Primary cultures of cortical astrocytes  
Primary astrocytes were prepared from cerebral cortex of 2–4 day old Balb/c mice (Pawlak and 
Beyer 2005). Astrocyte cultures were grown for 1 week at 37°C in a humidified incubator with 
5% CO2, and the medium was changed every third day. When reaching confluence, cells were 
passaged three times to remove microglia. 
 
5.3.2 Treatment of cell culture 
Before treatment with LPS, cortical astrocytes were kept for 48 h in serum-free neurobasal 
medium supplemented with 1% glutamine, 0.2% B27 (Invitrogen), streptomycin, and fungizone. 
All-trans RA (Sigma, St. Louis, MO, USA) and dexamethasone (Sigma) were dissolved in 
ethanol. Concentrations of 0.01, 0.1, or 1 μM RA or 1 & solvent only were added 12 h prior to 
LPS treatment. Then, 100 ng/mL Escherichia coli LPS (Sigma) was added, RA replaced with 
medium change, and cells were incubated for an additional period of 12 h. As a positive control 
for anti-inflammatory effects, 100 nM dexamethasone (Sigma) was added simultaneously with 
LPS. Putative cytotoxic effects on astrocytes were assessed with a LIFE/DEADTM 
viability/cytotoxicity assay (Molecular Probes, Eugene, OR, USA). In addition, we measured 
lactate dehydrogenase (LDH) release into the medium (Cytotoxicity Detection Kit; Roche 
Diagnostics, Mannheim, Germany). LDH release was normalized with respect to maximal 
release after treatment with 1% Trizol. 
 
5.3.3 Quantitative RT-PCR 
Total RNA was reverse transcribed into cDNA using M-MLV RT-kit (Promega, Mannheim, 
Germany) and random hexanucleotide primers (11 277 081 001; Roche) with calculated 
concentrations of 50 ng/μL RNA extract per reaction. Samples were diluted 1:10 after reverse 
transcription, and 2 μL were used for amplification with the LightCycler (Roche). Reactions 
were carried out in 10 μL volume/capillary with the QuantiTect kit (Qiagen, Hilden, Germany) 
containing 5 μL PCR master mix (including Sybr Green I, HotStarTaq DNA-polymerase, buffer, 
and MgCl2), nuclease-free water, the cDNA sample, and 0.5 μL primers (10 μM stock 
solutions). The protocol consisted of 15 min enzyme activation at 95°C, followed by 45 cycles of 
15-s denaturation at 94°C, 20-s annealing at the primer specific temperature, 20-s amplification 
at 72°C, and 5-s fluorescence measurement at 80°C. Primer sequences and melting temperatures 
are listed in Table 3. Expression of the housekeeping gene hypoxanthine-guanine 
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phosphoribosyl-transferase (HPRT) was measured to normalize gene expression. Melting curve 
analysis (from 65°C to 95°C, in 0.1°C/s) and agarose gel electrophoresis of the PCR products 
were routinely performed. Relative mRNA concentrations were determined using the second 
derivative maximum algorithm of LIGHTCYCLER software and crossing-point analysis of 
log/linear plots of fluorescence/cycle number.  
Concentration series to determine the PCR efficiency were therefore included in all runs. 
 
Table 3. Primer sequences used for quantitative RT-PCR 
 
 
5.3.4 ELISA for PGE2 
Cell culture supernatants were collected after 24-h incubation (same treatment protocol as for 
quantitative RT-PCR). The release of PGE2 into the supernatant was measured with a PGE2 
ELISA kit from Cayman Chemical (Ann Arbor, MI, USA) according to the manufacturer’s 
instruction. Included PGE2 standards were used to calculate the concentration of PGE2 and PGE2 
metabolites in 50 μL of 1:5 and 1:10 dilutions of the supernatants. 
 
5.3.5 Western blotting 
Samples were separated with discontinuous sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis, 2.5μg/slot, and transferred onto a nitrocellulose membrane. Protein transfer and 
equal loading were checked with Ponceau-S staining of the blots. Rabbit antisera were directed 
against COX-2 (diluted 1:2000, 160106; Cayman Chemical), actin (1:5000, A2066; Sigma), and 
a goat anti-serum was used against COX-1 (1:500, sc1754; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Indirect immunodetection was based on peroxidase-conjugated secondary 
antibodies (goat anti-rabbit, donkey anti-goat, both 1:5000; Sigma) and the enhanced 
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chemiluminescence method (Amersham Biosciences Europe, Freiburg, Germany) according to 
standard protocol. For semi-quantitative evaluation of protein expression X-ray films were 
exposed from 30 s to 20 min to determine the linear range of the signal, and signal intensities 
were evaluated with a digital image analysis system (LTF, Wasserburg, Germany). COX-1 and 
COX-2 immunoreactivity signals were normalized to the actin signals measured in the same blots 
after stripping. 
 
5.3.6 Immunocytochemistry 
After removal of the medium, cells were fixed and processed for standard immunocytochemical 
staining using a primary antibody against glial fibrillary acidic protein (GFAP; rabbit anti-mouse 
polyclonal antibody, 1:500, EnCor Biotechnology Inc., Gainesville, FL, USA). Polyclonal 
antibodies against retinoid receptors were obtained from Santa Cruz Biotechnology (sc-551, sc-
552, sc- 7387, sc-553, sc-831, sc-555; all diluted 1: 100). Secondary antibodies were Alexa Fluor 
546 goat anti-rabbit IgG (A-11010; MoBiTec) or Alexa Fluor 488 goat anti-mouse IgG (both 
1:2000, A-11001; MoBiTec, Göttingen, Germany). In addition, cell nuclei were stained with 
4’,6-diamidino-2-phenylindole dihydrochloride (1:1000). Results were evaluated with a Zeiss 
Axiophot epifluorescence microscope (Carl Zeiss, Oberkochen, Germany) coupled to an online 
digital camera (AXIOVISION software, Zeiss).  
 
5.3.7 Statistical analysis 
The effects of RA on LPS-stimulated astrocytes were measured for each condition in at least nine 
cultures prepared from three different litters, and the production of PGE2 was assessed in three 
independent cultures. The data were analyzed using ANOVA and post hoc Tukey test. The 
effects of RA on non-stimulated cultures were determined for each condition in at least six 
independent cultures prepared from two different litters and data were analyzed by Student’s t-
test. Measurements of COX protein expression were made in six astrocyte cultures from two 
litters, and from each preparation subcultures were submitted to the different experimental 
conditions. Data were tested with ANOVA and post hoc Tukey test. In the graphs, results are 
presented as means ± SEM. 
 
5.4 Results 
Astrocytes were isolated from cerebral cortex of neonatal mice. The applied protocol yielded 
primary cultures of > 95% GFAP-positive cells. Immunohistochemical data indicated that 
activated astrocytes in the rat spinal cord express RAR-α and RXRs, primarily RXR-β (Schrage 
 43 
et al. 2006; Jokic et al. 2007). In astrocyte primary cultures from rats, double 
immunofluorescence staining showed co-localization of GFAP and RAR-α, RAR-β, and RXR-α 
but low signal intensities of the other retinoid receptors (data not shown). 
 
5.4.1 LPS induces the expression of PG-synthesizing enzymes in astrocytes 
To rule out toxic effects of the chosen treatment conditions (100 ng/mL LPS and 1 μM all-trans 
RA, the highest of the experimental concentrations), we performed cell staining and 
viability/cytotoxicity assays based on intracellular esterase activity and plasma membrane 
integrity. No differences in cell density, cell morphology, and GFAP-staining were found 
between experimental groups (Fig. 9a). The percentages of dead cells were quantified (Fig. 9b 
and c). Living cells were identified by green fluorescence in the cytosol, whereas red nuclear 
staining (arrows) marked dead cells. The statistical analysis showed an average proportion of 
10% ± 2% dead cells (mean ± SEM) across the various experimental conditions and no 
significant effect of LPS or RA (ANOVA, Fig. 9c). These data were confirmed by LDH release 
assay. The concentration of released LDH, an indicator of cell death, was measured in culture 
supernatants of untreated cells and of cells that were exposed to LPS, RA, or both. Cells treated 
with the anti-inflammatory drug dexamethasone and LPS served as additional controls. LDH 
release after complete cell lysis with Triton X-100 was set as 100%. All culture conditions led to 
similar LDH concentrations in the supernatants (3.01% ± 0.12%, ANOVA not significant; Fig. 
9d). When astrocytes are challenged with inflammatory stimuli, a fast increase in eicosanoid 
synthesis is observed (Kalmar et al. 2001; Teather et al. 2002; Hsieh et al. 2007). We used 
bacterial LPS to simulate such an inflammatory situation in vitro. Using the Affymetrix 
GeneChip® Mouse Genome 430 2.0 Array (Affymetrix, Santa Clara, CA, USA) representing 
approximately 34000 well-characterized mouse genes, we found 85 genes to be up-regulated 
more than 30-fold by astrocytes after 12 h LPS treatment. Those included pro-inflammatory 
cytokines, chemokines, and most prominently, the PG synthesizing enzymes COX-2 and 
prostaglandin E synthase (PTGES) (Johann et al. 2008).  
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Figure 8. Treatment of astrocytes with lipopolysaccharides (LPS) and retinoic acid (RA) does not affect 
cell viability. (a) Immunocytochemical staining of cultured cortical astrocytes for glial fibrillary acidic 
protein (GFAP) (red) did not reveal any differences in cell density, morphological appearance, or GFAP 
immunoreactivity caused by LPS or RA treatment. Cell nuclei were stained with 4’,6-diamidino-2-
phenylindole dihydrochloride (blue). (b, c) Under all treatment conditions, astrocytes stained with the 
LIFE/DEAD viability/cytotoxicity assay contained a high percentage of viable cells (green) and only few 
dead cells (red nuclei, arrows). Statistical experiments, six different regions of each culture, showed no 
significant differences in cell survival. (d) Lactate dehydrogenase (LDH) release (n = 3 
cultures/experimental condition) was also not significantly affected by the treatments. LDH release is 
presented as percentage of maximal release, which was measured after complete cell lysis with 1% Triton 
X-100. The results imply that the cultivated murine astrocytes were not harmed by the experimental 
conditions. Error bars indicate SEM 
 
As the LPS-mediated induction of enzyme expression was maximal after approximately 12 h, 
this LPS stimulation period was chosen to investigate the pathways of PG metabolism and its 
modulation by RA. A summary of the enzymatic reactions involved in PG synthesis and 
degradation is outlined in Fig. 9.    
 
Figure 9. Prostaglandin (PG) synthesis in cortical astrocyte cultures. Cleavage of membrane 
phospholipids by the phospholipase A2 group IVa (cPLA2) leads to the generation of arachidonic acid 
which is subsequently converted by either cyclooxygenase 1 (COX-1) or COX- 2 to PGH2. Alternatively, 
arachidonic acid can be used as a substrate of lipoxygenases. The lipoxygenase 5 (Alox5) and its 
activating protein (Alox5ap) synthesize 5-hydroperoxy-5,8,11,13-eicosatetraeonic acid (5-HPETE) and 
initiate production of leuktrienes; strong mediators of early inflammation, whereas the action of 15-
lipoxygenase contributes to the production of anti-inflammatory lipoxins (pathway not shown). PGH2 is 
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the precursor of several PGs and thromboxanes. PGE2 is generated by the microsomal PGE-synthases 
(PTGEs) and is degraded by the 15-hydroxy-prostaglandin-dehydrogenase (HPGD). 
 
5.4.2 RA regulates LPS-induced expression of PG-synthesizing enzymes 
Effects of 100 ng/mL LPS and of LPS in combination with 0.01 μM, 0.1 μM, and 1 μM all-trans 
RA on gene expression were measured with quantitative RT-PCR. Transcript concentrations 
were normalized to those of the housekeeping enzyme HPRT, which was not altered after LPS 
stimulation (also compared with glyceraldehyde phosphate dehydrogenase and actin, data not 
shown). RA-dependent changes of mRNA concentrations were compared with the expression 
pattern of the corresponding enzymes in LPS-treated cultures, set as 100% (Fig. 11). Arachidonic 
acid, the common precursor of PG production, is released from membrane phospholipids. During 
inflammation, this step is mainly catalyzed by the group IV 
Ca2+-dependent phospholipase A2a (cPLA) and the group IIA secretory phospholipase A2 
(Funk 2001; Sun et al. 2004). According to the gene chip analysis, the latter enzyme was not 
expressed in cultivated astrocytes. In contrast, the cPLA enzyme was strongly expressed, and 
LPS treatment of astrocytes caused a highly significant fourfold up-regulation (Fig. 10a). RA had 
no influence on this effect (comparison with LPS, Tukey test: p > 0.1). Arachidonic acid is 
subsequently metabolized to PGH2. This reaction is catalyzed by COX enzymes. COX-1 is 
considered to be responsible for constitutive PG synthesis, whereas the isoenzyme COX-2 is 
responsible for PG production during inflammation. Whereas endotoxin stimulation reduced the 
expression of COX-1 to less than 2% of the expression in non-stimulated astrocytes, it led to a 
more than 50-fold increase in the expression of COX-2. In both cases, RA counteracted the effect 
of LPS (ANOVA, p < 0.01; Fig. 10b and c).  
The changes caused by 0.1 μM and 1 μM RA were highly significant (Tukey test, p < 0.01) or 
significant (p < 0.05 for the effect of 1 μM RA on LPS-induced regulation of COX-1). RA 
reduced the LPS-dependent expression of COX-2 by 30%. The microsomal PTGES converts 
PGH2 to PGE2, and the catabolic 15-hydroxyprostaglandin dehydrogenase (HPGD) is responsible 
for initiating the degradation of PGE2. After stimulation with LPS, PTGES was up-regulated 
more than 10-fold, whereas HPGD expression decreased by almost the same factor. Both effects, 
which would result in an increased availability of PGE2, were highly significant (Tukey test, p < 
0.01). Additional RA treatment did not significantly affect expression of these two enzymes (Fig. 
10d and e). Leukotrienes are potent inflammatory mediators usually synthesized by 
immunocompetent cells very early during inflammation.  
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Figure 10. Retinoic acid (RA) influences the effects of lipopolysaccharide (LPS) on expression of 
enzymes necessary for prostaglandin metabolism. Gene expression was quantified with real-time RT-
PCR. Cells were either treated 12 h with LPS or pre-treated 12 h with all-trans RA followed by 12 h 
exposure to LPS and RA. For each condition, mRNA concentrations of at least nine cultures from three 
litters were quantified. Concentrations were normalized according to the LPS-treated cultures. (a) LPS 
significantly amplified the expression of phospholipase A2 (cPLA). This was not changed by treatment 
with RA. (b) LPS reduced the expression of cyclooxygenase-1. RA antagonized this effect. (c) 
Cyclooxygenase- 2 (COX-2) was strongly induced by LPS. The inflammatory increase of COX-2 
expression was inhibited by RA in a dose dependent manner. (d) Prostaglandin E synthase (PTGES) 
expression was also amplified by LPS but this effect was not influenced by RA. (e) Expression of the 
metabolizing enzyme 15-hydroxy-prostaglandin- dehydrogenase (HPGD) was lower after LPS stimulation 
and not affected by additional RA treatment. Logarithmic plots; error bars indicate SEM. Following 
ANOVA, data were compared with the LPS-treatment condition, Tukey test. *p < 0.05, **p < 0.01. 
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Alox5 together with Alox5ap competes with COX enzymes for the substrate arachidonic acid. 
Alox5 converts arachidonic acid to 5-hydroperoxy-eicosatetraeonic acid, the substrate for 
subsequent leukotriene synthesis (Farooqui et al. 2007). The effects of LPS alone and together 
with 0.01 μM, 0.1 μM, and 1 μM RA on the transcription of Alox5 and Alox5ap are presented in 
Fig. 11. Endotoxin treatment was followed by a strong reduction of their transcript 
concentrations (p < 0.01) which again is likely to contribute to increased levels of PGs. RA had 
no additional or adverse effect (Fig. 11a, b). 
 
 
Figure 11. Enzyme expression of leukotriene metabolism is reduced by lipopolysaccharide (LPS) but not 
affected by additional retinoic acid (RA) treatment. (a) Changes in mRNA expression of lipoxygenase 5 
(Alox5) and (b) lipoxygenase 5 activating protein (Alox5ap). LPS treatment was followed by a strong 
reduction of Alox5 and Alox5ap expression. This effect was not altered by additional RA treatment. 
Experimental conditions as in Fig. 3. Every experiment was performed with at least nine cultures from 
three litters. Transcript concentrations were normalized according to the LPS-treated cultures. Error bars 
indicate SEM; ANOVA, Tukey test. **p < 0.01 vs. LPS treatment. 
 
5.4.3 RA reduces the LPS-dependent protein expression of COX-2 
To test whether the reduction of COX-2 mRNA expression caused by treatment with RA 
translates to the protein level, cell extracts were analyzed by immunoblotting. Astrocytes were 
treated as explained before. Under the control condition or after treatment with RA only, the 
COX-2 immunoreactivity was very low or not detectable, whereas 100 ng/mL LPS caused a 
strong increase in COX-2 protein expression. Consistently, pre- and continuing treatment with 
0.1 μM RA led to a much smaller increase (Fig. 12a). Compared to LPS stimulation, COX-2 
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immunoreactivity was reduced to 53% (n = 6, SEM = 8.9%), and this effect was highly 
significant (ANOVA, Tukey test, p < 0.001, Fig. 12b). The same protein samples were also 
analyzed with respect to the levels of COX-1 protein expression. We found that neither treatment 
of LPS or RA nor LPS + RA significantly affected the immunoreactivity of this enzyme (Fig. 12c 
and d).  
 
Figure 12. Retinoic acid (RA) reduces the lipopolysaccharide (LPS) - dependent protein expression of 
cyclooxygenase-2 (COX-2). Proteins in whole cell extracts of cultured astrocytes were analyzed by 
immunoblotting/ chemiluminescence. Experimental conditions were the same as explained for Fig. 3. (a) 
Western blot of a representative experiment shows almost non-detectable levels of COX-2 under control 
condition and RA treatment only, strong immunoreactivity after stimulation with LPS and a reduction of 
this effect when cultures were also treated with all-trans RA. (b) Quantification of protein expression 
normalized for actin immunoreactivity. Signal intensities were compared with the LPS condition set to 1. 
Experiments from n = 6 independent cultures, error bars indicate SEM, ANOVA, Tukey test. **p< 0.001. 
(c, d) The COX-1 signal in astrocyte cultures was not significantly changed by LPS exposure or RA 
treatment (ANOVA, values normalized to control condition). 
 
5.4.4 RA reduces the LPS-induced release of PGE2 
The observed changes in transcript levels of PG-related enzymes, specifically COX-2, imply that 
RA would reduce the LPS-mediated increase in PGE2 production. To test this, the release of 
PGE2 was measured in astrocyte culture supernatants using an ELISA. As expected, LPS 
strongly increased extracellular PGE2 concentration from approximately 8 pg/mL to 900 pg/mL. 
In accordance with the hypothesis, treatment with RA antagonized this effect in a highly 
significant manner (ANOVA, p < 0.01). The PGE2 concentration was reduced to about 500 
pg/mL by 0.1 μM RA and to 300 pg/mL by 1 μM RA (Tukey test, p < 0.01; Fig. 13). As a 
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positive control for the anti-inflammatory effect, we also applied the steroid dexamethasone, 
which is known to block PG synthesis.  
Dexamethasone prevented the LPS induced production of PGE2 almost completely.  
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Retinoic acid reduces the LPS-induced synthesis of prostaglandin E2. Astrocyte cultures were 
treated as described for gene expression analysis. For each condition (controls, 12 hrs LPS, 24 hrs 
RA + 12 hrs LPS, 12 hrs LPS + dexamethasone), PGE2 concentrations were measured by ELISA 
in two supernatant samples of three cell cultures. LPS strongly increased PGE2 production, and 
this effect was significantly suppressed by 0.1 and 1 FM RA in a dose-dependent manner. 
Dexamethasone, (Dex) used as an anti-inflammatory control, almost abolished the LPS-induced 
PGE2 production. Error bars indicate SEM, ANOVA, Tukey test ** p < 0.01 vs. LPS treatment. 
 
5.4.5 RA alters basal expression of eicosanoid metabolizing enzymes. 
Our main goal was to study anti-inflammatory effects of RA by investigating its influence on 
LPS-induced gene expression. As it was recently shown that RA can modulate basal PG 
metabolism of monocytes, neuroblastoma cells, and mesangial cells in vitro (Kim et al. 2004; 
Song et al. 2005; Alique et al. 2007), the effects of RA on the expression pattern of enzymes of 
PG metabolism were also studied in the absence of LPS (Fig. 14a). Transcript concentrations 
were normalized to the expression in non-treated cultures. We found that treatment with 0.1 μM 
all-trans RA significantly altered the expression of cPLA, Alox5ap, and COX-1 (t-test, p < 0.05, 
for each enzyme). RA reduced slightly but not significantly COX-2 expression and had no 
influence on transcript levels of PTGES and HPGD. Following RA treatment, the mRNA 
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concentration of COX-1 was doubled whereas expression of cPLA and Alox5ap was decreased 
by 50%. The effect of 0.1 μM RA on PGE2 release by astrocyte cultures was also measured 
(Fig.14b).  
The PGE2 concentration of approximately 8 pg/mL that was found in the supernatants of control  
cultures, was not significantly altered by RA treatment.  
 
 
Figure 14. Retinoic acid influences basal expression of prostaglandin metabolizing enzymes. Changes in 
mRNA expression of PGE2 synthesizing and metabolizing enzymes were measured in murine 
astrocytes following 24 hrs incubation with 0.1 μM RA. (a) For each condition, mRNA 
concentrations of at least six cultures from 2-3 different litters were quantified. Concentrations 
were normalized compared to untreated cultures. Treatment with RA doubled expression of 
COX-1, reduced cPLA and Alox5ap mRNA concentrations but had no influence on the basal 
gene activities of the other enzymes. Error bars indicate SEM, t-test, * p < 0.05 vs. control. (b) 
Changes in PGE2 release from cultivated astrocytes following 24 hrs incubation with 0.1 μM RA 
were measured by ELISA. RA treatment had no effect on PGE2 production. Error bars indicate 
SEM, n = 3 cultures, 2 replicates each. 
 
Although only relative changes in transcript concentrations were measured with LightCycler RT-
PCR, the crossing- point analysis gave a rough estimate of absolute mRNA concentrations in the 
cell extracts. With the different primers, all PCR amplification factors were in the range of 1.8–
2.0 amplifications/cycle. As indicated by crossing points between 24 and 26 cycles, basal gene 
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activities in the control extracts without LPS or RA treatment were highest for cPLA and COX-1. 
Amplification of COX-2, PTGES, and HPGD resulted in crossing-points ranging from 29 to 31 
cycles, suggesting a much lower level of gene expression.  
For comparison, housekeeping genes ,that were used for normalization had crossing-points at 
18/19 cycles (glyceraldehyde phosphate dehydrogenase) and 21/22 cycles (HPRT). 
 
5.5 Discussion 
We have investigated the expression of enzymes of eicosanoid synthesis in astrocytes, its 
regulation after LPS challenge, and the modulation of inflammatory reactions by RA. PGE2 
production was strongly enhanced 12 h after treatment with LPS. RA significantly reduced this 
inflammatory response. Investigation with quantitative RT-PCR revealed that this effect may 
have been caused by an RA mediated inhibition of the inflammatory up-regulation of COX-2. 
LPS strongly induced the expression of PGE2 synthesizing enzymes cPLA, COX-2, and PTGES, 
caused a decrease of the competing leukotriene synthesis pathway and a down-regulation of the 
PGE2 degrading enzyme HPGD. RA directly or indirectly counteracted the LPS-mediated effects 
on COX-1 and COX-2 but did not affect expression of other enzymes of PG metabolism. There 
was a highly significant inhibitory effect of RA on LPS-dependent PGE2 release. It is likely that 
this was because of the negative regulation of COX-2 expression by RA. In contrast to the 
general view that COX-1 is constitutively expressed (Tanabe and Tohnai 2002; Phillis et al. 
2006; Farooqui et al. 2007), we found that its mRNA levels were lower after exposure to LPS, 
and that this effect was partly inhibited by RA. On the protein level, however, no changes were 
observed. Treatment with RA alone significantly affected gene expression of cPLA, COX-1, and 
Alox5ap, but not of the other enzymes under investigation. A twofold increase in the COX-1 
mRNA concentration was measured, whereas cPLA and Alox5ap transcripts were reduced by 
approximately 50%. Again, RA alone did not alter protein levels of COX-1 as detected with 
immunoblotting. No significant changes in PGE2 release were apparent under this condition. 
 
5.5.1 Release of prostanoids by astrocytes during CNS inflammation 
The contribution of astrocytes to inflammatory processes in general and to eicosanoid production 
in particular has recently received increasing attention (Minghetti 2004; Tzeng et al. 2005). 
Several in vitro studies imply that PGE2 is the pre-eminent PG produced by astrocytes upon 
noxious stimulation. Inflammation inducing molecules like LPS (Kalmar et al. 2001), cytokines 
(Xu et al. 2003), or platelet-activating factor (Teather et al. 2002) stimulated astrocytes to 
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produce PGE2. The key steps of prostanoid synthesis are catalyzed by the COX enzymes. Two 
COXs occur in the nervous system, COX-1 and COX-2 (Phillis et al. 2006). As astrocytes 
showed a decrease in COX-1 expression after LPS treatment, the inducible COX-2 seems to be 
the crucial enzyme for the production of prostanoids during inflammation. Of all enzymes 
investigated in this study, the 50-fold induction of COX-2 mRNA was the most prominent effect, 
and this appears to be an anti-inflammatory target of RA in astrocytes. In line with these result, 
Kim et al. 2004 showed that RA reduced PGE2 production in LPS stimulated peritoneal 
macrophages. By incubating cells with exogenous arachidonic acid, they provided strong 
evidence that the reduction in PGE2 synthesis was because of decreased COX-2 availability and 
not regulation of arachidonic acid synthesis via phospholipase A2 (Kim et al. 2004). In a recent 
publication with microglia, the investigators report a more complicated temporal pattern of 
regulation: After 12 h of LPS treatment an increase of COX-2 was observed, which, similar to 
the present results was reduced by all-trans RA. Subsequently, however, expression of the 
enzyme declined and then increased again after 72 h. At that point in time, RA significantly 
enhanced the effect of LPS thus leading to a further increase in the production of PGE2. Release 
of the PG 15d-PGJ2, on the other hand, was not affected by RA (Kim et al. 2008). The question 
as to what extent astrocytes contribute to prostanoid synthesis in vivo is difficult to answer. 
Though contradictory studies have been published, a consensus emerges that astrocytes are 
important sources of prostanoids under pathological conditions (Minghetti 2004; Johann et al. 
2008). On the basis of immununohistochemical evidence, it appears that cortical and cerebellar 
astrocytes possess COX-2 in vivo and up-regulate its expression after kainate stimulation (Hirst 
et al. 1999). This is in accordance with results from neuropathological studies. For instance, in 
amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, and in experimental 
autoimmune encephalomyelitis, a model of MS, COX-2 expression was found to be enhanced in 
astrocytes (Minghetti 2004; Tzeng et al. 2005). Leukotrienes are also important early mediators 
of inflammation (Farooqui et al. 2007). Our investigation of genes associated with the initiation 
of leukotriene synthesis, Alox5, and Alox5ap yielded unexpected results. Untreated astrocytes 
expressed both proteins, but the transcript concentrations were significantly reduced after 12 h 
LPS treatment. Early changes of leukotriene synthesizing enzymes were not investigated in the 
experiments. Therefore, other inflammatory mediators that were increased, e.g., PGE2 might 
have inhibited the leukotriene and thromboxane pathways by regulatory feedback mechanisms.  
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5.5.2 Astrocytes as targets of RA signaling  
It is still largely unknown, how the astrocytic response during neuropathological processes is 
regulated. As retinoids exert anti-inflammatory effects (Racke et al. 1995; Dheen et al. 2005), 
they might affect astroglial reactions. We found RAR-α, RAR-β, and RXR-α to be expressed in 
rat astrocytes in vitro. In the rat spinal cord, RAR-α and RXR immunoreactivity was detected in 
astrocytes as well as in other cell types (Schrage et al. 2006; Jokic et al. 2007). Experiments with 
spinal cord contusion injury suggested that such a lesion triggers local RA synthesis in the CNS 
(Mey et al. 2005). Under these conditions, astrocytes appear to express RXR proteins and up-
regulated RAR-α expression at later stages of tissue damage (Schrage et al. 2006). Rats carrying 
a superoxide dismutase-1 mutation were used as a model for ALS. In these animals, at the end 
stage of disease, a marked increase in RXR-β staining was observed in astroglia in the spinal 
cord (Jokic et al. 2007). Though astrocytes are also discussed as a potential source of RA 
synthesis (Környei et al. 2007), information about the influence that RA exerts on astroglia in 
vivo is sparse. 
 
5.5.3 Anti-inflammatory effects of RA include the regulation of prostanoid synthesis 
Although several anti-inflammatory effects of RA were discovered in the last years (Kuenzli et 
al. 2004), only few studies focused on neuroinflammation. In rat primary microglia cultures 
stimulated with b-amyloid peptide or LPS, RA antagonized TNF-α and inducible nitric oxide 
(NO) synthase production, and induced transforming growth factor b1 synthesis (Dheen et al. 
2005). Racke and colleagues which showed that RA improved clinical outcome in the 
experimental autoimmune encephalomyelitis mouse model (Racke et al. 1995). This effect was 
accompanied by reduced IL-2, TNF-α, and interferon c transcription levels and by increased IL-4 
production. In another study, 9-cis RA attenuated the production of NO, TNF-α, IL-1β, and IL-
12 p40 by LPS-stimulated microglia and of NO and TNF-α by astrocytes (Xu and Drew 2006). 
As 9-cis RA binds to RARs and RXRs, these effects could have also been attained by activation 
of RAR independent mechanisms that involve RXRs, for instance peroxysome proliferator 
activating receptor signaling (van Neerven and Mey 2007). Though the influence of RA on 
eicosanoid metabolism has so far not been investigated in neuroinflammation, this interaction 
was studied in cancer research. The majority of reports suggest that RA counteracts 
pathologically enhanced synthesis of prostanoids (Mestre et al. 1997; Merritt et al. 2001; Li et al. 
2002; Wardlaw et al. 2002). An interference of RA signaling with the generation of transcription 
factors for the cAMP responsive element of the COX-2 promotor was discovered. Specifically, 
the activation of RAR-β inhibited the induction of c-Jun and activation of subsequent activator 
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protein 1 (AP1) (Mestre et al. 1997; Li et al. 2002; Song et al. 2005). Other experiments 
concurred by showing that RA antagonized COX-2 expression by limiting the transcriptional 
cofactors CBP and p300, which are crucial for AP1-induced transcription (Subbaramaiah et al. 
2002). The COX-2 promotor contains an NFκB site and a cAMP response element that is 
activated by the AP1 subunit c-Jun (Tanabe and Tohnai 2002). Thus, a suppression of COX-2 
up-regulation by RA could be caused by an inhibition of NFκB translocation (Na et al. 1999). 
Another possible mechanism may be the induction of suppressor of cytokine signaling-3 and 
thereby the inhibition of Janus kinase/signal transducer and activator of transcription signaling 
(Choi et al. 2005). A recent study of PG synthesis in microglia revealed opposite effects of RA at 
different periods of LPS stimulation, suggesting that more than one signal transduction pathway 
is involved (Kim et al. 2008). Although the molecular mechanism that is responsible for the 
influence of RA on LPS-induced COX-2 expression in astrocytes remains to be studied, the 
overall effect of RA on PG release during inflammation appears to be relevant for inflammatory 
regulation in vivo and may open a path for therapeutic intervention (Mey 2006). High eicosanoid 
concentrations are detrimental for neuronal survival. What is the physiological relevance of the 
RA effect on PG release? The availability of COX inhibitors prompted several investigations 
regarding the role of PGs in neuroinflammation. Reduced tissue damage and improved clinical 
outcome were reported (Araki et al. 2001; Minghetti 2004; Sun et al. 2004; Phillis et al. 2006). 
At present, three explanations as to how the inhibition of prostanoid synthesis might mitigate 
cellular damage are discussed. (i) Prostanoids cause the release of inflammatory cytokines, 
including TNF-α and IL-6, and immunoglobulins. This is accompanied by neuronal cell death 
(Fiebich et al. 1997; Araki et al. 2001; Zhang and Rivest 2001). (ii) Astrocytes have an important 
function in uptake and recycling of the neurotransmitter glutamate. As astrocytes release stored 
glutamate when stimulated with PGE2 (Bezzi et al. 1998) the inflammatory rise of PGE2 may 
contribute to a neurotoxic increase of the extracellular glutamate concentration (Drachman and 
Rothstein 2000). (iii) During prostanoid synthesis, the COXs release reactive oxygen 
intermediates (Gebicke-Haerter 2001; Teismann et al. 2003; Tzeng et al. 2005). The oxidation of 
membrane lipids, proteins, and nucleotides disturbs cellular functions, induces cell death, and is 
accompanied by severe damage of neurons and vascular cells. All these destructive effects could 
be abrogated by the inhibition of PG synthesis. Non-steroidal anti-inflammatory drugs improve 
the course of neurological diseases as they limit the extent of inflammatory damage by inhibiting 
prostanoid synthesis. Prostanoids have been implicated in ALS, MS, PD and AD. In most cases, 
an observed increase of PGE2 was considered to be neurologically detrimental (Klivenyi et al. 
1998; Drachman et al. 2002; Maihofner et al. 2003; Teismann et al. 2003). If our in vitro data, 
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showing a mitigating effect of RA on inflammatory COX-2 expression and PGE2 release, 
represent a similar function in vivo, it is likely that RA reduces neurotoxicity and may also 
influence local cytokine levels in a way to maintain tissue homeostasis. 
 
5.5.4 What is the significance of the regulation of basal prostanoid metabolism by RA? 
Basal prostanoid concentrations are drastically lower than under inflammatory conditions. 
Nevertheless, eicosanoid signaling is involved in non-pathological brain physiology, including 
synaptic activity and the regulation of blood flow. COX inhibitors interfere with long-term 
potentiation, which was reversible by additional PGE2 application (Minghetti 2004; Phillis et al. 
2006). It was concluded that PGE2 contributes to synaptic rearrangements by modifying 
monaminergic signaling, cytoskeleton structure, and post-synaptic excitability (Minghetti 2004). 
The COX-2 enzyme is also expressed by neurons where it is concentrated in distal dendrites and 
dendritic spines. It is up-regulated during neuronal activity. Astrocytes are important regulators 
of synaptic plasticity. We report here that RA altered mRNA expression of cPLA, COX-1, and 
Alox5ap in the absence of LPS, and indirect evidence suggests that RA is involved in synaptic 
plasticity (Chiang et al. 1998; Misner et al. 2001; Cocco et al. 2002). Whether PG signals from 
astrocytes have a function in this context remains to be investigated. Systemic RA treatment 
enhanced COX-2 expression in the rat spinal cord which correlated with allodynic and 
hyperalgesic responses to mechanical and thermal stimuli (Romero-Sandoval et al. 2004; Alique 
et al. 2006). An RA-induced differentiation of neuroblastoma cells was accompanied by an up-
regulation of COX-1, COX-2, and enhanced PGE2 production (Schneider et al. 2001; Alique et 
al. 2007). Distinct from the predominant anti-inflammatory effects discussed above, RA 
therefore appears also to regulate prostanoid synthesis under non-inflammatory conditions in 
different ways. 
 
5.5.5 Conclusion 
This study demonstrates that RA affects prostanoid synthesis in cultivated cortical astrocytes. 
Under conditions of LPS induced inflammation, RA reduced COX-2 transcript and protein levels 
and PGE2 production. The data support an anti-inflammatory role of RA as already suggested by 
published effects on cytokines. In non-stimulated astrocytes, RA enhanced COX-1 and reduced 
Alox5ap on the level of mRNA expression. These differential effects of RA on prostanoid 
metabolizing enzymes depending on the inflammatory status suggest at least two distinct 
functions. On the one hand, RA may reduce excitotoxicity and inflammatory autoreactivity by 
limiting the pathological prostanoid synthesis. On the other hand, RA may stimulate basal 
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prostanoid metabolism and could thereby influence physiological functions including blood flow 
or synaptic plasticity. 
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6.  Brain region-specific astroglial responses in vitro after LPS exposure 
 
6.1 Abstract  
Astroglia is well-known to be integrated in the complex regulation of neuroinflammation in the 
central nervous system. Astrocytes become activated and synthesize cytokines, chemokines, and 
prostanoids during degenerative and vulnerable processes and interact with other immune-
competent cells. Degenerative disorders often occur in a brain-region-specific fashion suggesting 
differences in the activity and reactivity of innate immune cells. We have investigated the 
potency of lipopolysaccharides (LPS) to differently stimulate astrocytes from the cortex and 
midbrain. Astroglial cultures were prepared from Bagg albino/c mice and exposed to LPS. 
Astrocytes from both brain areas already differed in their capacity and profile of cytokine 
expression under basal unstimulated conditions. In response to LPS, we observed both a region-
specific pattern of up-regulation of distinct cytokines and differences in the extent and time-
course of activation. Our data demonstrate that astrocytes reveal a region-specific basal profile of 
cytokine expression and a selective area-specific regulation of cytokines upon LPS-induced 
inflammation. This makes astrocytes likely candidates to be responsible for region-specific 
incidence rates of neurological and neurodegenerative disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
6.2 Introduction 
Neuroglia, comprising micro- and macroglia, has diverse functions in the mammalian central 
nervous system (CNS). Microglia is mainly implicated in inflammatory processes, whereas 
macroglia, encompassing oligodendrocytes and astrocytes, fullfill a magnitude of functions that 
are essential for the establishment and function of brain circuits. Besides playing an important 
trophic and metabolic role for neurons, astrocytes are approved to be involved in inflammatory 
processes of the CNS (Aloisi et al. 2000; Dong and Benveniste 2001; Farina et al. 2007; Fisher et 
al. 2007). Astrocytes participate in brain prostanoid metabolism, thus modulating brain-intrinsic 
physiological processes in a paracrine manner through the synthesis of prostaglandins, 
thromboxanes, and leukotrienes (Tzeng et al. 2005; Johann et al. 2008). This type of glia cell also 
synthesizes and secretes inflammation-related cytokines and chemokines under pathological 
conditions (Farina et al. 2007; Fisher et al. 2007; Kipp et al. 2007). Among them, the pro-
inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1) appear to be 
prominently produced by astrocytes (Chung and Benveniste 1990). The latter function may 
explain the importance of astroglial cells for inflammatory and degenerative processes in the 
brain (Darlington 2005). Specific attention has been paid to astrocytic dysfunctions in relation to 
MS (MS; Williams et al. 2007), PD (PD; Hald and Lotharius 2005), stroke (Wang 2005; 
Maragakis and Rothstein 2006), and ALS (Moisse and Strong 2006). It is intriguing that 
neuropathological processes are often characterized by brain-region-specific pathological events 
and cell loss. In particular, the susceptibility of neurons to pro-inflammatory stimuli such as LPS 
and, subsequently, neurotoxicity exhibits region-specific characteristics. This phenomenon may 
be attributable to differences in microglial presence and function, i.e., production of 
inflammation-related factors in the affected brain area (Kim and Joh 2006). Regional diversity in 
microglial IL-1 expression has been reported and linked to IL-1-mediated and astrocyte-
dependent production of alpha- 1-antichymotrypsin, which is known to act as a pathological 
chaperone and binds to amyloid β protein (Das and Potter 1995). In addition, regional differences 
in LPS-induced IL-1 production in the CNS change throughout life span and are accompanied by 
an age-related cellular localization of IL-1R1 expression (Huh et al. 2001). At first glance, such 
region-specific innate immune responses seem to be restricted to microglial properties and 
activating mechanisms. On closer examination, however, microglia-astroglia interactions are 
always implicated in this process and the selective contribution of astrocytes seems to be 
essential for the induction and cessation of neural inflammation (Das and Potter 1995; Maragakis 
and Rothstein 2006; Williams et al. 2007). This applies to PD and AD as highlighted by Das and 
Potter (1995) and McGeer and McGeer (Das and Potter 1995; McGeer and McGeer 2008). In 
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addition, the striking selective neuronal vulnerability from cerebral neocortical and hippocampal 
neurons as a consequence of transient global ischemia may be the result of regional glial 
properties and presumably be explained by differences in local glutamate metabolism, water 
transport capacities, and therefore glutamate-induced swelling (Bernaudin et al. 1998; Han et al. 
2004; Karakaya et al. 2007). Thus, the cross-talk between neural cells including neurons and the 
different glial cell types may converge in a vicious cycle of autocrine and paracrine interactions, 
which cause the amplification of inflammation, perpetuation of tissue damage, and finally 
neuronal cell loss (Takuma et al. 2004; Mosley et al. 2006). These findings led us to hypothesize 
that astroglial cells from different brain regions vary with respect to their basal expression rate of 
cytokines and/or their responsiveness upon stimulation of inflammatory processes. We have 
mimicked a bacterial infection in cultured cortical and midbrain mouse astrocytes by treating 
cells with the endotoxin LPS (Pistritto et al. 1999; van Noort 2006) and analyzed cytokine 
expression using Affimetrix Gene Chip and Cytokine Antibody Arrays as well as enzyme-linked 
immunosorbent assay (ELISA) techniques. 
 
6.3 Material and Methods 
 
6.3.1 Primary culture of astrocytes 
Primary astrocytes were prepared from 1-4 days old Balb/c mice (Harlan Winkelmann GmBH, 
Germany) as described (Pawlak et al., 2005; Kipp et al., 2007). The resulting final astroglia 
culture is characterized by >95% homogeneity of glial fibrillary acidic protein (GFAP)-positive 
cells and no microglial or neuronal contamination (Pawlak and Beyer, 2005). 
 
6.3.2 Treatment of cultures 
Astrocytes were used for experiments after the third replating and before reaching confluency. 
Before starting treatments, astrocytes were kept for 48 h under serum-free conditions with 
neurobasal medium (NBM; Invitrogen, Germany) supplemented with 1% glutamine, 0.2% B27 
(Invitrogen, Germany), penicillin/streptomycin (0.5%), and fungizone (0.1%) for 48 h. Cells 
were exposed to 100 ng/ml Escherichia coli LPS (Sigma, Germany) for 12 h. This dose was 
found in previous experiments to be most effective in inducing cytokine expression by astrocytes 
(Kipp et al., 2007). 
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6.3.3 Affymetrix Gene Chip array 
After LPS-treatment, total RNA sample collection and generation of biotinylated complementary 
RNA probes was carried out essentially as described in the Affymetrix GeneChip® Expression 
Analysis Technical Manual (Affymetrix, Santa Clara, CA, USA. Genes which differ in their 
expression levels by a factor of two or greater in all experiments were selected to be up-
regulated. 
 
6.3.4 Quantitative RT-PCR 
Gene expression of enzymes was measured using the rtPCR technology (BioRad, Germany), 
QTM SYBR Green Supermix (BioRad, Germany), and a standardized protocol as described 
previously (Johann et al., 2008). Reactions were conducted in standard tube using the 
MiniOpticon rtPCR Detection System (BioRad, Germany) under following conditions: 10 min 
enzyme activation at 95°C, 45 cycles of 15 s denaturation at 95 °C, 30 s annealing at individual 
temperatures, 30 s amplification at 72 °C, and 5 s fluorescence measurement at 80°C. The 
following primer sequences were used: IL-6, sense (s) tct gac cac agt gag gaa tgt, antisense (as) 
tgc agt cac aga agg agt ggc (bp length 151); TNF-α, (s) acc cct tta ctc tga ccc c, (as) gag tcc ttg 
atg gtg gtg c (bp length 188); housekeeping reference gene (HPRT), (s) gtc ggt gaa aag gac ctc t, 
(as) cac agg act aga ac acct gc (bp length 248). Finally, data were expressed as the ratio of the 
amount each transcript versus the concentration of HPRT. Melting curves and gel electrophoresis 
of the PCR products were routinely performed to determine the specificity of the PCR reaction. 
 
6.3.5 Antibody Array 
Quantitative assessment of a selected subset of cytokines was performed using a commercially 
available array-based technology, RayBioTM Cytokine Angiogenesis Antibody Array 
(RayBiotech Inc., Atlanta, USA). Array membranes were incubated with 2 ml of cell culture 
supernatants at 4°C overnight. After several washing steps, bound cytokines were visualized 
according to the manufacturer’s protocol. The sensitivity of the cytokine antibody array was 1 
pg/ml for each of the cytokine. Densitometrical quantification (OD measurement) was performed 
with an AlphaImager system (Alpha Innotech, USA). 
 
6.3.6 ELISA 
Cell culture medium were harvested and centrifuged at 900xg for 5 min to remove cell debris. 
Supernatants were frozen in liquid nitrogen and stored until analysis. Following cytokines were 
determined using an ELISA according to the manufacturer’s instructions (Invitrogen, Germany): 
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Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Cytokine concentration in the cell 
culture supernatant was calculated by interpolation from standard curves provided by the 
manufacturers. Sample analysis was performed in triplicates in three independent experiments. 
Finally, data were expressed as the ratio of the amount of TNF-α/IL-6 versus entire protein 
amount per well. 
 
6.3.7 Statistical analysis 
A total of nine independent experiments were performed each consisting of 2-5 wells for each 
treatment/condition. For each independent culturing, cortical and midbrain tissues from 5-6 
neonatal mice were pooled. Time-course experiments were tested in triplicate experiments. For 
the Antibody Array, a total of three independent culture experiments (n=3) with 2 
wells/treatment was performed. For ELISA and rtPCR experiments, six independent experiments 
(n=6) with 3 wells/treatment were analyzed. Statistical differences between groups were tested 
by two-way ANOVA test of variance followed by the post-hoc Tukey multiple-range test using 
SPSS with p<0.05 as the criterion for significant differences. 
 
6.4 Results 
Our study aimed to obtain information about regional differences in cytokine expression of 
cultured astrocytes and its regulation after LPS exposure, which mimics bacteria-induced 
inflammatory processes in this cell type (Palsson-McDermott and O'Neill 2004). Recently, we 
have demonstrated that cultured neonatal astroglia from both brain regions express all LPS-
receptive proteins required for LPS signaling, i.e., MD-2, CD-14, TLR-4, and Myd88 (Johann et 
al. 2008). In preliminary experiments, we have analyzed gene expression profiles of different 
cytokines in cultured cortical astrocytes under control conditions and after LPS challenge for    
12 h using an Affymetrix Gene Chip array (Table 4).  
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Table 4. Selection of LPS-regulated genes in cortical astrocytes detected by Affimetrix Gene Chip array 
 
The table summarizes the regulation of 
selected cytokine genes in cultured cortical 
astrocytes exposed for 12h to LPS (100 
ng/ml). Three independent Affimetrix gene 
arrays were performed as described in the 
section Materials and Methods. For 
abbreviations see text. +, 5-8fold up-
regulation; ++, > 8fold up-regulation. For 
abbreviations, see text. 
 
This preliminary study revealed that cortical astrocytes contain mRNAs of a large set of 
cytokines, chemokines, and related proteins at different levels, most of them showing low-to-
moderate expression levels (data not shown). This is in good agreement with previously 
published data (Kipp et al. 2006; Kipp et al. 2007; Johann et al. 2008). To contain the large 
multiplicity of relevant factors, we have further focused on those cytokines that are known as 
major inflammatory mediators and discussed under the paradigm of neurodegeneration. Table 4 
summarizes several cytokines and chemokines, which were found to be highly up-regulated after 
LPS treatment. To assure that mRNA expression is also reflected by protein expression and 
secretion and for further quantitative analysis, we have employed a cytokine/chemokine antibody 
array, which covers the proteins detected by the Affymetrix Gene Chip array and adds additional 
pro-inflammatory factors. The analysis comprised, at first, the basal expression and secretion 
pattern of cytokines into the culture supernatant (Fig. 15). 
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Figure 15. Expression of different cytokines in cultured (A) cortical (Cx) and (B) midbrain (Mes) 
astrocytes detected by a cytokine protein chip assay. (C) Summary of all tested cytokines and their 
position on the chip. Spots were densitometrically analyzed and optical densities (OD) quantified. OD 
data were normalized against internal standards. Quantitative data shown in (D) represent the means +/- 
SEM from three independent culture experiments. LPS-regulated proteins are marked in bold, and 
percentile as well as significance values are given. C, control. For further abbreviations see text. Post-hoc 
Tukey multiple-range test, *p<0.05 C vs. LPS; **p<0.01 C vs. LPS; ***p<0.001 C vs. LPS. 
 
In unstimulated control cultures of both brain areas, all tested factors were detectable. A more 
detailed statistical testing identified already under basal conditions significant differences in the 
quantity of the expression profile of different proteins between cortex and midbrain astrocytes. In 
particular, granulocyte macrophage colony stimulating factor (GM-CSF), IL-13, and regulated on 
activation, normal T-cell expressed and presumably secreted (RANTES) were present at 
significantly higher levels in the cortex compared to the midbrain, whereas IL- 2, M-CSF, P-
Selectin, and MIP-3α were conversely reduced in cortical astroglia (Fig. 16). The exposure to 
LPS not only resulted in a similar induction of some proteins in both brain regions but also 
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disclosed differential regulation of others (Figs. 15 and 16). The expression of G-CSF, IL-2, and 
P-selectin was only stimulated in cortical glial cells by LPS (Fig. 15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Regional differences in basal cytokine and chemokine expression of astrocytes. Quantitative 
data derive from experiments shown in Figure 15 and represent the means +/- SEM from three 
independent culture experiments. Expression levels of cytokines and chemokines in midbrain astrocytes 
were each set to 100%, and proteins in cortical astrocytes are shown as percentile of midbrain values. 
Statistical analysis was performed with raw data. Data represent means +/-SEM from 3 independent 
experiments. Post-hoc Tukey multiple-range test, *p<0.05 cortex vs. midbrain; **p<0.01 cortex vs. 
midbrain; ***p<0.001 cortex vs. midbrain. 
 
In contrast, IL-1α, IL-5, IL-6, MCP-1, MCSF, MIP-3α, RANTES, and TNF-α were all 
significantly increased after LPS challenge in midbrain and cortical astrocytes although to a 
different extent. By comparing the magnitude of induction between regional astrocytes, we 
observed that IL-1α and TNF-α were promoted in the midbrain at significantly higher rates 
compared to the cortex, whereas the expression of MCP-1, MIP-3α, IL-2, and G-CSF was much 
more excited in the cortex (Figs. 15 and 17).  
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Figure 17. Regional differences in LPS-induced cytokine and chemokine expression of astrocytes. 
Quantitative data given as absolute ODs derive from experiments shown in Figure 15 and represent the 
means +/- SEM from three independent culture experiments. Data represent means +/-SEM from 3 
independent experiments. Statistical analysis was performed with raw data. Post-hoc Tukey multiple-
range test, *p<0.05 control vs. LPS; **p<0.01 control vs. LPS; ***p<0.001 control vs. LPS. 
 
In order to survey the validity of the chosen methods, for further quantitative examination, and to 
obtain better information about the time-course of cytokine induction, we have compared the 
profiles of IL-6, which is promoted in both regions to similar extent, and TNF-α, which shows a 
highly-specific regional profile. Expression of both cytokines was measured by rtPCR and 
ELISA to assure protein and mRNA data against each other. The LPS-induced increase of TNF-
α mRNA expression was already seen after 1 h and, thereafter, increased stepwise to highest 
values at 12 h (Fig. 18A). Differences between the midbrain and cortex became obvious after 4 h. 
ELISA data confirmed these observations and indicated elevated TNF-α protein levels after 2 h 
(Fig. 18B). 
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Figure 18.Time-course of LPS-induced (12 h, 100 ng/ml) stimulation of TNF-α mRNA (A) and TNF-
α protein (B) expression. Levels of mRNA were quantified by real-time PCR and are given as percent of 
control (C). Protein levels were measured by ELISA and are given in pg/ml. Note the different time-
course and final TNF-α levels between midbrain and cortical astrocytes. Data represent means +/-SEM 
from six independent experiments. Statistical analysis was performed with raw data. Post-hoc Tukey 
multiple-range test, *p<0.05 control vs. LPS; **p<0.01 control vs. LPS 
 
 
Again, higher TNF-α protein amounts were detected in the midbrain. LPS-treatment provoked an 
increase of IL-6 in midbrain and cortical cells (Fig. 19A/B). This LPS-effect became first 
apparent after 4 h and increased further until 12 h. No difference in the extent of stimulation was 
detectable between both brain regions.  
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Figure 19. Time-course of LPS-induced (12 h, 100 ng/ml) stimulation of IL-6 mRNA (A) and IL-6 
protein (B) expression. Levels of mRNA were quantified by real-time PCR and are given as 
percent of control (C). Protein levels were measured by ELISA and are given in pg/ml. Note the 
similar time-course and final IL-6 levels in midbrain and cortical astrocytes. Data represent 
means +/-SEM from six independent experiments. Statistical analysis was performed with raw 
data. Post-hoc Tukey multiple-range test, *p<0.05 control vs. LPS. 
 
6.5 Discussion 
The CNS is widely regarded as a privileged and partially insular immune site (Farina et al. 2007). 
Recent observations, however, have sustainably altered this point of view and pointed out that 
the CNS is neither isolated nor passive in its interactions with the immune system or invading 
pathogens (Carson et al. 2006). Resident glial cells have been shown to act in an immune-
competent way, thus providing the settings of the brain-intrinsic immune system for an adequate 
response and functional interface with brain-extrinsic immune cells in relation to local 
inflammation and neurodegeneration (Aloisi et al. 2000; Carson et al. 2006). Besides microglial 
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cells that are considered as major resident immune-competent cells in the brain, astrocytes appear 
to execute important steps of early-immune responses and contribute to the synthesis of local 
immune modulators (Suzumura et al. 2006). Under neuropathological conditions such as 
demyelination and cellular degeneration, astrocytes become activated and regulate the survival 
and death of neurons and oligodendrocytes by releasing cytokines and other pro-apoptotic factors 
(Chung and Benveniste 1990; Bernaudin et al. 1998; Maragakis and Rothstein 2006; Farina et al. 
2007). In addition, astroglia is responsible for scar formation and, as a consequence, inhibition of 
axonal restoration after deleterious brain events (Farina et al. 2007; Williams et al. 2007). 
Interestingly, neuroinflammation appears to be a double-edged sword, since astrocytes can also 
convey neuroprotective and neurotrophic effects at distinct stages of CNS pathology by 
providing growth factors and regulating extracellular levels of excitotoxic glutamate (Franzen et 
al. 2004). Recent discoveries revive the concept that immunological or inflammatory challenges 
might be an etiological factor in sporadic cases of neurological disorders (Nguyen et al. 2002). In 
fact, molecules of the innate and adaptive immune system, including astrocyte-derived immune 
modulators, are implicated in the pathogenesis of several neurological disorders, i.e., PD, MS, 
and stroke (Mennicken et al. 1999; Lucas et al. 2006). It is apparent that many neurological 
diseases and pathological processes reveal local brain region- and cell-type-specific criteria 
(Calabresi et al. 2000; Kostrzewa and Segura-Aguilar 2003). The importance of glial-cell-
propagated neuroinflammation for local neurodegeneration indicates a more active role of 
astrocytes in the pathophysiology of acute and progressive chronic neurological disorders, such 
as AD, ALS, MS, PD, and stroke (Skaper 2007). From these finding, a new concept has emerged 
that favors the importance of neuron-glia intercommunication and a more dynamic role of 
astrocytes by integrating neuronal activity as well as glia-to-glia signaling demonstrated by glia-
derived cytokine release and cytokine-dependent regulation of glutamate metabolism during 
neurodegeneration (Vesce et al. 2007). This view is corroborated by data presented in this study. 
Recently, we have identified astroglia as a major source of brain-endemic prostanoids and 
cytokines (Kipp et al. 2007; Johann et al. 2008). In this study, we show that astrocytes prepared 
from Balb/c mice respond in a local way to inflammatory activation. Such a local glia 
specification is demonstrated by not only by differences in the basal expression profile and basal 
expression levels (see Fig. 15) of cytokines and other immunmodulators between midbrain and 
cortical astrocytes but also by massive differences in the stimulation profile of those factors. It 
needs to be mentioned that the source of astrocytes used in this study is the neonatal brain and 
that the observed reactivity toward pro-inflammatory stimuli and the region-specific response of 
astroglia may change throughout life. This is of particular interest when considering the active 
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role of glial cells in the regulation and prevention of neurodegenerative processes in the CNS. 
Expression pattern of CSFs was different under basal conditions (GM-CSF higher in the cortex, 
M-CSF higher in the midbrain) and after LPS stimulation (M-CSF and GCSF higher in the 
cortex). CSFs are hematopoietic cytokines widely used to stimulate proliferation and 
differentiation of neutrophilic, eosinophilic, and monocyte lineages. CSFs and its receptor are 
known to be expressed in the brain and to affect various brain functions under pathological 
conditions (Franzen et al. 2004). In the pathological “quiescent” CNS, astrocytes seem to be the 
unique source of some CSFs (Malipiero et al. 1990). Several reports assign CSFs an important 
role in CNS pathogenesis. In stroke, G-CSF decreases infarct volumes thus providing a beneficial 
function (Schneider et al. 2005), In MS, GM-CSF has a key role for inflammatory demyelinating 
lesions and the control of migration and/or proliferation of leukocytes within the CNS, thus being 
deleterious to neurons (Franzen et al. 2004). CSFs have also numerous effects on microglia, 
ranging from induction of proliferation to changes in their morphology. Since microglial 
progenitors arise from peripheral mesodermal myeloid tissue (Chan et al. 2007), CSFs secreted 
from astrocytes are likely candidates for astroglial–microglia interactions. 
By further comparison of the magnitude of LPS effects, we found that IL-1α and TNF-α are 
promoted in the midbrain at significantly higher rates compared to the cortex. This is also 
demonstrated by the respective expression kinetics. TNF-α is a pleiotropic cytokine originally 
recognized for its anti-tumor activity but now referred to be a pro-inflammatory factor that plays 
a central role in the initiation of the immune cascade and the regulation of other cytokines. This 
makes TNF-α an important control instance for immune responses due to infection in the CNS 
(Allan and Rothwell 2001). A robust increase in TNF-α expression levels in the CNS is seen in 
experimental models of acute injuries and chronic brain diseases such as PD (Gosselin and 
Rivest 2007). PD is a movement disorder caused by a pronounced degeneration of nigrostriatal 
dopamine neurons in the substantia nigra and a resulting dopamine deficiency in the in the 
striatum. It is obvious that inflammatory processes contribute to the pathogenesis of PD. 
Increased levels of pro-inflammatory cytokines such as TNF-α and IL-1 were described in the 
nigrostriatal region of post mortem brains and in the cerebrospinal fluid from patients with 
sporadic PD (McGuire et al. 2001). In an animal model, systemic LPS application caused 
progressive neurodegeneration of dopamine neurons through TNF-α signaling (Qin et al. 2007). 
The involvement of TNF-α, IL-1, and IL-6 in experimentally induced dopaminergic cell loss 
during PD has also been stressed by others (Nagatsu and Sawada 2005). However, these studies 
emphasized only the importance of local microglia but not astroglia. Interestingly, local 
microglia in vitro derived from the midbrain appeared to be more sensitive and responsive to 
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LPS compared to hippocampal microglia (Kim et al. 2000). This is in good accordance with our 
observations but turns the attention in equal measure to astrocytes. Together, these observations 
indicate that the differential region-specific susceptibility of midbrain neurons to inflammation 
and cell degeneration is attributable to differences in the responsiveness and mobilization of 
micro- and astroglia (Teismann and Schulz 2004).  
Rapid and resounding biological answers of astrocytes upon exposure to LPS are due to the 
expression of a set of Toll-like receptors (TLRs), which recognize bacterial lipoproteins. The 
TLR family is a major class of pattern recognition receptors that has emerged as a central player 
in the initiation and tailoring of both innate and subsequent adaptive immune responses (Jack et 
al. 2005). TLR 1, TLR2, and TLR6 were assigned in some reports to be responsible for LPS 
signal transduction in astrocytes (Farina et al. 2007; Krasowska-Zoladek et al. 2007). Other 
groups, however, reported that astrocytes express robust TLR3, low-level TLR1, 4, 5, and 9, and 
rare-to-undetectable TLR2, 6, 7, 8, and 10 mRNA (Jack et al. 2005). It might be assumed that 
astrocytes from different brain regions are equipped with different subsets of TLRs, which in turn 
may account for such local glial reaction. From previous mouse studies, we know that cortical 
and midbrain astrocytes express the same set and levels of LPS receptors, including MD-2, 
CD14, TLR4, and Myd88, which are comparably up-regulated by LPS (Johann et al. 2008). In 
human astrocytes, other TLRs appear to be effective (Farina et al. 2005). To date, no clear-cut 
regional diversity in LPS signaling within the CNS has been documented. Therefore, differences 
in the cellular LPS-receptive system are not likely to be the cause for the observed disparity of 
astrocytes in their responsiveness toward LPS. Further studies are required to resolve this issue. 
In conclusion, we have presented data showing that astrocytes from different brain regions 
exhibit distinct local differences in the baseline expression of pro-inflammatory factors and 
responsiveness upon inflammatory stimuli. We assume that such functional disparities of 
astrocytes along with microglia performance contribute to the pathogenesis of neurological 
disorders such as PD and others. 
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7. Estrogen and progesterone reduce LPS-induced expression of TNF-alpha and 
interleukin-18 in midbrain astrocytes  
 
7.1 Abstract 
Besides microglia, astrocytes exert an important regulatory function in the initiation and control 
of neuroinflammatory processes in the CNS. Clinical and experimental data suggest that sex 
steroids are neuroprotective and that neurological/neurodegenerative disorders display sex-
specific characteristics. Astroglia are known to respond to toxic stimuli by secretion of distinct 
pro-inflammatory/apoptotic cytokines. In this study, we have investigated the influence of 
estrogen and progesterone on the expression of the cytokines TNF-α and IL-18 in primary 
astrocytes obtained from neonatal mouse midbrain and cerebral cortex after the stimulation with 
lipopolysaccharides (LPS). LPS strongly induced the expression of TNF-α in astrocytes from 
both brain regions and IL-18 in those from midbrain. Estrogen significantly attenuated LPS-
induced TNF-α expression in the midbrain glia but not in the cortex glia. Combined treatment 
with estrogen and progesterone together diminished LPS-induced IL-18 expression in the 
midbrain completely. Both steroid effects could be specifically antagonized by the steroid 
hormone receptor antagonists ICI 182,780 and mifepristone. We conclude that neuroprotective 
estrogen and progesterone effects in the midbrain might be in part the consequence of a reduced 
pro-inflammatory response of astroglia. 
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7.2 Introduction 
There is broad evidence from clinical and experimental data that estrogen is neuroprotective in 
the brain. Estrogen can reduce toxic damage to neurons, stimulate cell viability and survival, and 
balance neurodegenerative destruction (Garcia-Segura et al. 2001; Kajta and Beyer 2003). The 
cellular mechanisms responsible for neuroprotection by estrogen include a direct influence on 
apoptotic processes in neurons but also interactions with non-neuronal cells such as microglia 
and astrocytes. In particular, astrocytes which express receptors for sex steroids (Pawlak et al. 
2005; Bains et al. 2007) are considered to play a major role in estrogen-mediated neuroprotection 
in the CNS (Azcoitia et al. 2001). Estrogen has been shown to regulate growth factor supply 
(Granholm 2000) and glutamate metabolism (Pawlak et al. 2005) in astroglial cells, thus 
controlling survival-promoting physiological processes. On the other hand, estrogen counteracts 
cytokine-mediated apoptosis in cultured neurons (Kajta et al. 2006). In addition, progesterone 
also possesses neuroprotective properties (Callier et al. 2001). Besides microglia, which has a 
well-characterized function during inflammation in the CNS, astrocytes are also known as 
inflammatory mediators in the brain. Astrocytes intensively interact with T-cells and microglia 
and, in addition, express a wide array of chemokines and pro-inflammatory cytokines such as 
TNF-α and IL-18 (Dong and Benveniste 2003; John et al. 2003; Wen et al. 2007). Since TNF-α 
and IL-18 are actively regulated during brain injury and inflammation as well as in MS or AD, 
they represent direct regulatory targets for steroid-dependent cellular protection (Kipp et al. 
2006; Lucas et al. 2006).  
Sex steroids are well-known to interfere with pro-apoptotic cytokine production in different cell 
types and organ systems including the brain (Olsen and Kovacs 1996; Angele et al. 2000; Wang 
et al. 2006). This is generally supported by the influence of gender on responses to soluble 
inflammatory mediators such as LPS (Coyle et al. 2006) and presumed to play a role as a cause 
of gender differences in neurological disorders (Czlonskowska et al.). In the uterus, estrogen 
inhibits IL-1b-mediated inflammatory effects (Schaefer et al. 2005), and progesterone was found 
to down-regulate TNF-α expression (Maruo et al. 2003). In the CNS, sex steroids attenuate 
endotoxin-dependent cytokine responses in the human hypothalamus (Puder et al. 2001) and 
have notably a considerable impact on microglia cell activation (Bruce-Keller et al. 2000; Drew 
and Chavis 2000). To which extent other neural cell types, e.g. astroglia, contribute to the 
established sex steroid-related mitigation of inflammatory processes in the brain is at present not 
clear. Therefore, this study attempted to identify the influence of estrogen and progesterone on 
LPS-induced inflammatory responses in astroglia cultures from neonatal mouse midbrain and 
cerebral cortex.  
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7.3 Material and Methods 
 
7.3.1 Cell culture treatment 
Astroglial cultures were prepared and propagated as described in several studies (Ivanova et al. 
2002; Pawlak et al. 2005; Bains et al. 2007). Cells were treated with the endotoxin LPS in order 
to mimic bacterial inflammatory processes (Perry and Andersson 1992). Pre-treatment with 
steroids or antagonists was done for 24 h prior to LPS exposure.  
 
7.3.2 Quantitative RT-PCR 
Gene expression was analysed by semi-quantitative RT-PCR (TNF-α) (Ivanova et al. 2002) or by 
light cycler (IL-18) (Pawlak et al. 2005).  
 
7.3.3 TNF-α  ELISA 
TNF-α protein in the culture supernatant was measured using an ELISA technique (Kajta et al. 
2006).  
 
7.3.4 Statistical analysis 
Five independent experiments, each consisting of triplets per treatment and analysis were 
performed. Data were statistically analyzed by ANOVA followed by a post-hoc t-test. 
 
7.4 Results  
Expression of TNF-α mRNA and protein in non-stimulated astrocytes from both brain areas was 
very low (Figure 1A/B). Basal IL-18 mRNA levels were also low in astrocytes from both brain 
regions but higher as compared to TNF-α. Treatment with LPS (100 ng/ml) at different time 
intervals (1-24 h) revealed that a 4 h stimulation period yielded maxima in TNF-α and IL-18 
mRNA expression (only tested in midbrain cultures).  
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Figure 20. Effect of estrogen (E, 10-8M) and progesterone (P, 10-8M) pre-treatment (24 h) on LPS-
induced (4 h) tumour necrosis factor-alpha (TNF-α expression in midbrain and cortical neonatal 
astrocytes. (A) Semi-quantitative RT-PCR analysis. (B) ELISA for TNF-α. LPS-stimulation (4 h) 
increased TNF-α mRNA and protein expression in astrocytes of both brain regions about 3-fold compared 
to controls (C). Pre-treatment with E significantly reduced LPS effects in the midbrain but not in the 
cortex (a, p < 0.01 E vs. LPS). The application of P had no effect. The simultaneous treatment with E and 
the estrogen receptor antagonist ICI 182,780 (ICI) completely inhibited the E effect (b, p < 0.01 E + ICI 
vs. E).  
 
Time course (percent increase compared to controls) was: TNF-α 1 h (factor 1.9 compared to the 
control level), 4h (6.8), 12 h (4.5), and 24 h (4.0); IL-18 1 h (1.3), 4h (1.8), 12 h (1.2), and 24 h 
(1.1). This demonstrates that the induction of TNF-α and IL-18 in astrocytes follows a different 
kinetic and regulation. No significant LPS-stimulation of IL-18 was observed in cortical 
astrocytes (Figure 2). Conti et al. (Conti et al. 1999) have already described that LPS treatment 
does not affect constitutive IL-18 expression in cerebral astrocytes, whereas a robust increase 
was found in cerebral microglia.  
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Figure 21. Effect of estrogen (E, 10-8M) and progesterone (P, 10-8M) pre-treatment (24 h) on LPS-
induced (4 h) interleukin-18 (IL-18) expression in midbrain and cortical astrocytes. LPS treatment 
stimulated IL-18 expression 1.8-fold (a, p < 0.01 LPS vs. control, C) in midbrain but not cortical 
astrocytes. The exposure of astrocytes to E or P prior to LPS-stimulation resulted in a significant 
reduction of IL-18 mRNA expression by approx. 50% (b, p < 0.01 E vs. LPS and P vs. LPS). Treatment 
with both steroids together further decreased IL-18 levels to C values (c, p < 0.05 E+P vs. E or P). Both 
steroid effects were antagonized by the simultaneous application of the E/P nuclear receptor antagonists 
ICI 182,780 (ICI) for E and mifepristone for P (d, p < 0.05 E+P plus ICI/RTI vs. E+P).   
 
In general, stimulation of IL-18 expression in the midbrain after LPS was 1.8-fold compared to 
control. This is in contrast TNF-α where LPS-mediated increase was up to 8-fold compared to 
controls. LPS exposure for 4 h did not cause toxic effects in astrocytes as determined by a LDH 
assay in the culture medium (Kajta et al. 2006). During the chosen time intervals (1-24 h) of LPS 
exposure, LDH levels fluctuated only by approx. 5% compared to untreated controls. Pre-
treatment with estrogen (10-8M) but not with progesterone (10-8M) 24 h prior to LPS application 
(4 h) significantly (p < 0.01 vs. LPS) attenuated TNF-α induction on the mRNA and protein level 
in midbrain astrocytes (Figure 1 A/B). The effect of estrogen was completely inhibited by the 
simultaneous intervention with the estrogen receptor antagonist ICI 182,780 (p < 0.01 ICI vs. 
estrogen). No influence of progesterone on LPS-induced TNF-α expression was found in cortical 
astrocytes. The expression of IL-18 mRNA was only significantly increased (p < 0.01 vs. 
control) by LPS in midbrain astrocytes but not in cortical cells (Figure 2). In contrast to TNF-α, 
both steroid hormones impeded the LPS-induced increment of IL-18 in midbrain astrocytes to a 
similar extent (p < 0.01 vs. LPS). The application of both steroids together further abated IL-18 
expression resulting in values similar to controls. Again, ICI 182,780 and mifepristone (RTI, 
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progesterone receptor antagonist) completely prevented the effect of estrogen and progesterone 
(p < 0.05 vs. steroids). Treatment with both steroids alone in the absence of LPS had no influence 
on TNF-α or IL-18 mRNA levels in both brain regions (not shown). Dose-dependency of 
estrogen and progesterone effects on TNF-α ELISA) and IL-18 (light cycler), respectively, was 
tested in the midbrain in the range of 10-10M-10-6M. Estrogen/TNF-α (pg), 10-6M (200 +/- 4), 10-
8M (205 +/- 6), 10-10M (249 +/- 5); progesterone/IL-18 (OD), 10-6M (129 +/- 5), 10-8M (136 +/- 
4), 10-10M (155 +/- 5). 
 
7.5 Discussion 
Ovarian steroids can protect the brain against injury and neurodegeneration (Garcia-Segura et al. 
2001; Kajta and Beyer 2003; Bains et al. 2007; Azcoitia et al. 2001; Granholm et al. 2000). 
Attention is usually given to estrogen, whereas the protective role of progesterone has been 
underestimated for a long time. It is now obvious that both steroids can equally act protective in 
the CNS (Alkayed et al. 2000; Stoll et al. 2000; Grossmann et al 2004). Cytokines are crucial 
mediators of neuroinflammation and acute/chronic degeneration in the CNS (Kipp et al. 2006; 
Lucas et al. 2006). The studied pro-inflammatory factors, TNF-α and IL-18, are both locally-
produced and released during brain inflammation and stroke by microglia and reactive astroglia 
(Mehlhorn et al. 2000; Garcia-Ovejero et al. 2005; 2006). During traumatic injuries in the CNS 
and spinal cord, the expression of the estrogen-forming enzyme aromatase and progesterone 
synthesis is promoted in astrocytes and Schwann cells (Garcia-Ovejero et al. 2005). In addition, 
astrocytes are capable of progesterone de novo synthesis (Akwa et al. 1993). This implies that 
locally-synthesized sex steroids may contribute to the complex scenario of pro-inflammatory but 
also anti-apoptotic processes during brain injury and pathology (Stoll et al. 2000; Alkayed et al. 
2004; Lucas et al. 2006). In activated microglia, it has been demonstrated that sex steroids 
repress TNF-α production (Grossmann et al. 2004) and interfere with inflammatory activation of 
this cell type (Garcia-Ovejeroet al. 2005). Our data now clearly reveal that such hormonal effects 
can also be observed in midbrain astrocytes. Both sex steroids significantly diminished or 
abolished the induction of TNF-α and IL-18 in midbrain astroglia. Interestingly, no effect was 
observed in cortical astrocytes although cortical as well as midbrain astroglial cells express 
estrogen and progesterone receptors (Pawlak et al. 2005; Kipp et al. 2006). The cause of this 
region-specificity is at the moment not clear. A number of in vitro and in vivo studies have 
furnished proof that estrogen and to a lesser extent progesterone are important neuroprotective 
compounds for midbrain dopamine neurons during experimentally-induced cell damage and in 
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human PD (Dluzen 2000; Sawada et al. 2000; Callier et al. 2001; Sawada et al. 2002; D´Astous 
et al. 2003). Although the protective mechanisms activated in the midbrain by sex steroid are 
complex and often interwoven (Kajta and Beyer 2003; Kipp et al. 2006), our data clearly suggest 
that hormonal inhibition of cytokine synthesis may contribute to the decreased severity of 
neuropathological stimuli and neurotoxic events commonly associated with inflammatory 
episodes in the midbrain. Previously, it has been demonstrated that estrogen mediates 
neuroprotection in the midbrain via estrogen receptor-beta and the activator protein-1 (AP-1) 
(Sawada et al. 2002). In accordance, midbrain astrocytes express high levels of estrogen 
receptor-ß (Pawlak et al. 2005). The expression of cytokines, and in particular TNF-α, is 
regulated by AP-1 (Liu 2005; Mahesh et al. 2006). The discovery that increased levels of TNF-α 
are causally-linked to PD (Nagatsu and Sawada 2005) and that estrogen modulates TNF-α 
expression in microglia through estrogen receptor-beta (Baker et al. 2004) are supportive for the 
idea that estrogen-dependent neuroprotection in the midbrain are due to an attenuation of pro-
inflammatory cascades. Moreover, gender differences in the prevalence and degree of 
neurological disorders associated with midbrain dopamine systems may additionally be the 
consequence of differences in the hormonal milieu in vivo (Anderson et al. 2005; Czlonkowska et 
al. 2006). Thus, circulating and/or locally-formed sex steroids may have a symptomatic as well 
as neuroprotective influence in the CNS. 
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8. GENERAL DISCUSSION 
The main focus of this study was to characterize the inflammatory potential of primary astrocytes 
in vitro in terms of prostanoid metabolism and cytokine production. The treatment with the 
endotoxin LPS was selected to mimic a bacterial infection of neural tissue (Uematsu et al. 2002). 
Astrocytes have previously been shown to be responsive to LPS stimulation (Palsson-McDermott 
and O’Neill 2004). I have corroborated and widened these data by gene expression studies which 
revealed that astrocytes express receptive proteins for signal transmission of LPS including TLR-
4. The administration of LPS yielded in an intense expression of COX-2, associated with the 
increased production of PGE2. Additionally, the expression and release of several pro-
inflammatory cytokines was highly elevated. Beyond that, the expression profile of cytokines 
was found to vary in astrocytes of different brain regions. Treatment with the female sex 
hormones estrogen and progesterone significantly depleted the release of the cytokines TNF-α 
and IL-18. The vitamine A derivative retinoic acid counteracted the up-regulation COX-2 protein 
and the production of pro-inflammatory PGE2. 
 
 In the last decade, the concept of neuroinflammation and neurodegeneration in the CNS has 
dramatically shifted from the pure understanding of neuronal cell death and cell protection to the 
unraveling the responsible cell-cell interactions implicated in the neuropathology and 
neuroprotective mechanisms. In the focus of this emerging new research field came non-neuronal 
cells and, in particular astrocytes. The contribution of this glial cell type for brain development, 
the maintenance of many neuron-related functions, and neuroprotection is well-documented. 
Recently established was their massive influence and participation in inflammatory processes.  
Besides their manifold functions in regulation the brain homeostasis, astrocytes can respond very 
rapid to inflammatory stimuli with an induction of several genes and the release of cytokines, 
chemokines, and prostanoids (Johann et al. 2008; Kipp et al. 2008). Prostanoids are generated 
from arachidonic acid which is released by the activity of cPLA2. COX-2, the key enzyme for 
PGE2 production converts AA to a main precursor for all other prostanoids. Cyclooxygenase-2 
expression and PGE2 release was found to be up-regulated in various neurodegenerative diseases, 
including Parkinson’s disease (Teismann et al., 2003), AD (Yermakova and O’Banion 2000) and 
ALS (Pompl et al., 2003; Minghetti, 2004). Tzeng et al. (2005) inferred from their studies that 
astrocytes are an important source of PGE2 during neuroinflammation, although microglia 
appears to produce higher amounts of prostaglandins. In my experimental setup, LPS triggered 
the induction of the anabolic enzymes cPLA2, COX-2 and PTGES and, at the same time, 
diminished the expression of the metabolic enzyme HPGD. As a consequence, LPS-exposure of 
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astrocytes resulted in an intense augmentation in PGE2 production and accumulation which was 
further supported by an impaired degradation of PGE2 by HPGD. PGE2 is involved in regulation 
of various processes of acute and chronic inflammation, such as vasodilatation, pain 
hyperalgesia, and fever. Based on these observations, high amounts of PGE2 during 
inflammatory processes are not only due to an increased COX-2 expression but also to an 
impaired degradation of prostaglandins. In contrast, COX-1 is described as constitutively 
expressed and responsible for physiologically relevant PGE2 production (Farooqui et al., 2007). 
In this context, it is noteworthy that PGE2 at modest levels and defined conditions is necessary to 
modulate neuronal function in a beneficial way through the regulation of microcirculation and 
synaptic function (Haydon and Carmignoto, 2006). 
Cytokines are critical inflammatory mediators and are involved in acute/chronic degeneration in 
the CNS (Kipp et al. 2006; Lucas et al. 2006). The investigated pro-inflammatory factors, TNF-α 
and IL-18, are locally-produced and released during brain inflammation by reactive glia 
(Mehlhorn et al. 2000). TNF-α is referred to be a pro-inflammatory factor that plays a central 
role in the initiation of the innate immune response and the regulation of other cytokines. This 
makes TNF-α an important control instance for immune responses due to infection in the CNS 
(Allan and Rothwell 2001). By the characterization of LPS effects, I found that IL-1α and TNF-α 
expression is facilitated in mesencephalic astrocytes at significantly higher levels compared to 
cortical astrocytes. Heterogeneity among astrocytes indicates that their position in the CNS is 
more multifunctional than is commonly recognized. Given this diversity, it is assumable to 
expect that, the genes expressed by astroglia during brain injury and neurodegeneration will vary 
according to the type of astrocytes and the brain region in which it is located. It is assumed that 
several neurological diseases and other neuropathological processes display local brain region- 
and cell type-specific characteristics (Calabresi et al. 2000; Kostrzewa and Segura-Aguilar, 
2003). For example, PD is characterized by the progressive loss of dopaminergic neurons 
primarily in the substantia nigra pars compacta. ALS is characterized by progressive 
degeneration of the upper motor neurons in the cortex and the lower motor neurons in the 
brainstem and spinal cord. Inflammatory processes have been shown to be linked with the 
pathogenesis of ALS and PD. Reactive astrocytes are found in the region associated with cell 
loss, possibly contributing to the inflammatory process by the release of pro-inflammatory 
prostaglandins and cytokines (Forno et al. 1992; Pehar et al. 2005). Numerous reports document 
that neuronal and non-neuronal cells in the CNS are potential targets for lipophilic hormones, 
such like female sex steroids and retinoic acid. Astroglia have been shown to express receptors 
for estrogen and progesterone as well as receptors for retinoic acid (Chattopadhyay and Brown, 
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2001; Kipp et al. 2006; Lucas et al. 2006; Schrage et al. 2006). Vitamin A can protect the brain 
against injury and neurodegeneration (Granholm et al. 2000; Azcoitia et al. 2001; Garcia-Segura 
et al. 2001; Kajta and Beyer 2003; Bains et al. 2007). 
Retinoids which include vitamine A and its derivatives are important for the correct development 
of the vertebrate CNS. They also control multiple functions in the adult including vision, cell 
differentiation, immunity, and the homeostasis of many tissues. Thus, during both early phases of 
development and continuing through adulthood, retinoids are critical for normal physiology. 
Retinoic acid is considered to have anti-inflammatory properties and is used therapeutically for 
skin diseases and certain cancers (Chalker et al. 1987). However, only some studies have 
addressed the role of RA in neuroinflammation and neuroprotection. I found a highly significant 
inhibitory effect of RA on LPS-dependent COX-2 expression and PGE2 release in astrocytes. 
Several reports propose that RA antagonizes pathological caused synthesis of prostaglandins, by 
suppressing COX-2 in different kind of cancer (Merritt et al. 2001; Li et al. 2002). An 
interference of RA signaling with the transcriptional activators CRE, C/EBP or NFκB pathway is 
assumed, depending on the stimulus and the cell type (Chun and Surh, 2004). 
Gonadal hormones are known to be of major importance in the normal maintenance of brain 
function. Data from epidemiological studies suggest that the decline in estrogen following 
menopause may increase the risk of neurodegenerative disorders, such as AD, MS, and stroke. 
Following menopause, a drastically age-related decrease in serum estrogen occurs due to an 
exhaustion of ovarian follicles, such that postmenopausal women have estrogen levels 
approximately 10% of pre-menopausal women. This might, at least in part, explain the 
relationship of estrogen deficiencies and an increased risk for women to suffer a stroke or 
neurodegenerative diseases. Although the reason for some gender differences in neurological 
diseases, including ALS and MS is still unknown, the concentration of estrogens or progesterone 
may be involved, or the expression of their receptors. I found that both female sex hormones 
significantly diminished the induction of TNF-α and IL-18 in midbrain astroglia with the greatest 
effect when they were applied in combination. Interestingly, no effect was observed in cortical 
astrocytes although expression for estrogen and progesterone receptors has been demonstrated 
(Pawlak et al. 2005). The different capabilities of astroglial to release cytokines might influences 
inflammatory processes during neurodegeneration in distinct brain regions. 
My findings led to a research concept concerning the part of astroglial inflammatory properties 
and the role of nuclear hormones in neurodegenerative disorders. In fact, it was shown that 
dysfunctions of astroglia might be accountable for neurodegeneration, but with the open question 
whether these are primary or secondary effects. The dysregulation of the inflammatory responses 
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by astroglial cells is also associated with acute neuropathological disorders such as stroke and 
brain trauma. It became also obvious that astroglia are part of the complex immunological 
machinery including brain-resident and brain-extrinsic immuncompetent cells. In my opinion, 
however, astrocytes play a major initial regulatory role, since they are present during very early 
steps at the site of inflammation. Thus, they possess the capability to control the first detrimental 
responses. I assume that prostanoids and cytokines synthesized by activated astroglia are 
promising candidates to be involved in the generation of ALS, MS, and AD where a close 
relationship between astroglia and prostanoids has been shown. Nevertheless, the cellular targets 
of astroglia-mediated toxicity during neuroinflammation remain elusive. It is of interest that later 
during acute brain pathologies, astrocytes switch from a destructive phase which is taken over by 
other cell types to a protective function. Clarifying the signaling pathways of sex steroids and RA 
in astrocytes will define additional therapeutically roles for this molecule on cytokine and 
prostanoid metabolism during brain inflammation. This novel insight into neuroinflammation 
will allow in future to directly targeting astrocytes by pharmaceutical therapies in order to 
attenuate or even abolish the vulnerable processes, i.e. pro-inflammatory responses, and to 
activate protective mechanisms.  
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9. SUMMARY 
Glial cells in the CNS are supportive and nutritive for neurons. Furthermore, they regulate the ion 
milieu and energy homeostasis in the CNS. During development, they stimulate via growth 
factors and other developmentally active agents the differentiation of neural systems. 
Importantly, they are the key regulators of extracellular glutamate levels. In addition to these 
many functions, astrocytes are actively incorporated in the control of neuroinflammation and 
neurodegeneration. Besides microglia, astrocytes appear to play a dynamic role during brain 
inflammation and neuronal degeneration. Retinoic acid has recently been shown to be involved 
in the regulation of neuroinflammatory processes. Since reactive astrocytes produce a distinct set 
of inflammatory cytokines (IL-1β, IL-6, IFN-γ, and TNF-α) and prostaglandins, they are 
predestinated to initiate, perpetuate, and terminate immunological processes in the brain. Thus, 
astroglial-derived immunomodulatory factors are integrated in the complex scenario of glia-glia 
and glia-neuron cell to cell communication during pathological processes. I have shown for the 
first time in detail that mouse neonatal cortical astroglia is capable to express and regulate several 
cytokines and the complete enzymatic machinery of prostanoid synthesis and degradation upon 
stimulation with lipopolysaccharides (LPS) which mimics a bacterial infection. I have presented 
data revealing that astrocytes from different brain regions possess distinct local differences in the 
baseline expression of pro-inflammatory mediators and sensitivity upon inflammatory stimuli. 
Treatment with LPS caused a massive up-regulation of and enzymes responsible for 
prostaglandin E2 (PGE2) formation as well as a down-regulation of such enzymes which catalyze 
PGE2 degradation. As a consequence of LPS application, we observe a rapid and temporarily 
restricted PGE2 release from cortical astrocytes. This clearly highlights the importance of 
astrocytes in circumscribed inflammatory areas in the CNS and raises the question to what extent 
astroglia is pivotal for the further regulation of immuncompetent cells and their activity. 
Further experimental approaches suggest that nuclear hormones, including estrogen (E), 
progesterone (P) and retinoic acid (RA) can function as important immune-modulators. They also 
take part in the regulation of prostanoid and cytokine synthesis in astrocytes. Astrocytes were 
shown to express several subtypes of E/P and RA receptors. The simultaneous administration of 
sex steroids or RA significantly attenuated many of the observed LPS effects on cytokine and 
prostanoid metabolism, thus, yielding a considerable reduction of TNF-α, IL-18, COX-2 
expression and PGE2 release.  
In conclusion, my data suggest an active role for astroglia in brain cytokine and PGE2 synthesis 
under neuropathological conditions. Sex steroids and retinoic acid appear to be very effective in 
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the suppression of TNF-α, IL-18 and PGE2 production and might, therefore, be a useful tool for 
clinical treatment of neuroinflammatory processes in the brain. 
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10. ZUSAMMENFASSUNG 
Astrozyten spielen eine entscheidende Rolle bei der Ernährung von Nervenzellen und sind für die 
Aufrechterhaltung eines konstanten Ionenmilieus sowie für die Energiehomöostase im ZNS 
verantwortlich. In der frühen Entwicklung steuern sie über Wachstumsfaktoren und andere 
wichtige Proteine die Differenzierung neuronaler Systeme. Sie sind entscheidend für die korrekte 
Regulation der extrazellulären Glutamatkonzentration. Daneben sind Astrozyten maßgeblich an 
der Initiation und Regulation von neuronalen Entzündungsprozessen beteiligt. Neben der 
Microglia, den ZNS-spezifischen Makrophagen, spielen Astrozyten eine zentrale Rolle bei 
entzündlichen und degenerativen Prozessen im Gehirn. Reaktive Astrozyten produzieren eine 
Vielzahl pro-inflammatorischer Zytokine (IL-1β, IL-6, IL-18, IFN-γ, and TNF-α) und 
Prostanoide. Die Freisetzung dieser Faktoren spielt eine maßgebliche Rolle für Zell-Zell 
Kommunikation zwischen Gliazellen und zwischen Glia und Nervenzellen unter pathologischen 
Prozessen.  
Prostanoide sind Arachidonsäurederivate unterteilen sich in Prostaglandine und Thromboxane. 
Prostaglandin E2 (PGE2) ist neben Prostaglandin I2 das wichtigste physiologische Prostaglandin, 
das in das Entzündungsgeschehen involviert ist. Ich konnte in meinen Versuchsansätzen zum 
ersten Mal detailliert beschreiben, daß kortikale Astrozyten von neugeborenen Mäusen nach 
einer Stimulation mit Lipopolysacchariden (LPS), das als Model für eine bakterielle Infektion 
verwendet wird, die entscheidenden Enzyme zur Prostanoidsynthese und zum -abbau 
exprimieren. Eine Behandlung mit LPS führte zu einer starken Erhöhung der Expression 
verschiedener Zytokine und aller für die PGE2 Synthese wichtigen Enzyme, sowie zu einer 
Reduktion der PGE2 katabolisierenden Enzyme. Dies zusammen führt zu einer raschen und 
zeitlich und lokal begrenzten Zunahme des extrazellulären PGE2. Diese Befunde zeigen sehr 
deutlich die Bedeutung der Astroglia für lokale entzündliche Vorgänge im Gehirn. Daraus ergibt 
sich die Frage, inwieweit diese initialen, glialen Prozesse für die weitere Regulation anderer 
immunkompetenter Zellen unter pathologischen Prozessen sind. Lipophile Liganden wie 
Steroide und Retinsäure (RA) sind wichtige Regulatoren der Genexpression und erzielen ihre 
Wirkung durch Bindung an spezifische nukleäre Rezeptoren. Retinsäure und 
Geschlechtshormone sind eingebunden in komplexe Vorgänge wie Reproduktion, Zellwachstum 
und Zelldifferenzierung. In Bezug auf neuroinflammatorische Abläufe zeigen Steroide und  
Retinsäure ihre Wirkung u.a. darin, daß sie spezifisch in die Regulation der Zytokin-und 
Prostanoidsynthese eingreifen. Astrozyten exprimieren verschiedene Subformen von Östrogen-, 
Progesteron- und RA-Rezeptoren. Die gleichzeitige Gabe von Hormon und LPS zeigte, daß 
gonadale Steroide und RA die stimulierende Wirkung von LPS auf  TNF-α, IL-18 und PGE2 
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Bildung deutlich abmilderten. Zusammenfassend läßt sich festhalten, daß die Astroglia eine in 
der PGE2 Bildung besitzt, bakterielle Infektionen zu einer Induktion der Zytokin- und 
Prostaglandin- Synthese führen, und weibliche Geschlechtshormone und RA protektiv wirken 
können. Dies läßt uns schlußfolgern, daß nukleäre Hormone auch für den klinischen Einsatz bei 
neuralen Entzündungen eine Rolle spielen könnte. 
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